WO1999043703A1 - Technique de dosage immunochimique de l'anticorps anti-hm1.24 - Google Patents
Technique de dosage immunochimique de l'anticorps anti-hm1.24 Download PDFInfo
- Publication number
- WO1999043703A1 WO1999043703A1 PCT/JP1999/000885 JP9900885W WO9943703A1 WO 1999043703 A1 WO1999043703 A1 WO 1999043703A1 JP 9900885 W JP9900885 W JP 9900885W WO 9943703 A1 WO9943703 A1 WO 9943703A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- soluble
- antigen
- protein
- antigen protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Definitions
- the present invention relates to a method for immunochemical measurement of an anti-HM1.24 antibody.
- the present invention also relates to a method for immunochemically measuring soluble HM1.24 antigen protein. Further, the present invention relates to a soluble HM1.24 antigen protein and a DNA encoding the same.
- mice have reported a mouse monoclonal antibody 1.24 that recognizes an antigen with a molecular weight of 22-39 kDa, specifically expressed in the B cell lineage, obtained by immunizing human plasma cells. (Blood (1994) 84, 1922-1930).
- This mouse anti-HMl.24 antibody shows in vivo antitumor effect in mice transplanted with human plasma cells and in vitro antitumor effect on human plasma cells by ADCC (anti body-dependent cellular cytotoxicity) activity (Ozaki, S et al., Blood, (1997) 90, 3179-3189) o
- the anti-HM1.24 antibody and its antigen, the HM1.24 antigen protein expressed on the cell membrane, have already been reported as described above.
- methods for detecting or measuring soluble HM1.24 antigen protein or low concentrations of soluble HM1.24 antigen protein or anti-HM1.24 antibody have not been known.
- the present invention provides a simple method for detecting or measuring a low concentration of soluble HM1.24 antigen protein or anti-HM1.24 antibody.
- the present invention provides (1) an anti-HM1.:24 antibody bound to a soluble HM1.24 antigen protein by reacting a soluble HM1.24 antigen protein with an anti-HM1.24 antibody contained in a test sample. And a method for immunochemically measuring an anti-HM1.24 antibody, comprising the step of detecting or measuring
- the soluble HM1.24 antigen protein is preferably fused to another peptide or polypeptide.
- the soluble HM1.24 antigen protein is preferably associated with a support.
- the support is preferably a bead or a plate.
- the soluble HM1.24 antigen protein is preferably supported by antibodies to other peptides or polypeptides fused to soluble HM1.24 antigen protein or soluble HM1.24 antigen protein. Is combined with
- the present invention also provides (2) detecting or measuring an anti-HM1.24 antibody bound to a soluble HM1.24 antigen protein with a primary antibody against the anti-HM1.24 antibody.
- the present invention is also characterized in that (3) detecting or measuring the anti-HM1.24 antibody bound to the soluble HM1.24 antigen protein using a primary antibody against the anti-HM1.24 antibody and a secondary antibody against the primary antibody.
- the method for immunochemical measurement according to the above (1) or (2) is provided.
- the primary or secondary antibody is preferably labeled with a radioisotope, an enzyme, piotin avidin or a fluorescent substance.
- the present invention also provides (4) a method of reacting an anti-HM1.24 antibody with a soluble HM1.24 antigen protein contained in a test sample to form a soluble HM1.24 antigen protein bound to the anti-HM1.24 antibody.
- a method for immunochemically measuring a soluble HM1.24 antigen protein comprising a step of detecting or measuring a protein.
- the soluble HM1.24 antigen protein is preferably fused to another peptide or polypeptide.
- the HM1.24 antibody is preferably bound to a support.
- the support is preferably a bead or a plate.
- the anti-HM1.24 antibody is bound to the support, preferably by an antibody against the anti-HM1.24 antibody.
- the present invention also provides (5) another peptide obtained by fusing a soluble HM1.24 antigen protein bound to an anti-HM1.24 antibody with a primary antibody against the soluble HM1.24 antigen protein or a soluble HM1.24 antigen protein.
- the present invention provides the immunochemical measurement method according to the above (4), which is detected or measured by a primary antibody against the polypeptide.
- the present invention also provides (6) a soluble HM1.24 antigen protein bound to an anti-HM1.24 antibody, a primary antibody against the soluble HM1.24 antigen protein or another peptide or polypeptide fused to the soluble HM1.24 antigen protein.
- the primary antibody or the secondary antibody is preferably labeled with a radioisotope, an enzyme, piotin / avidin or a fluorescent substance.
- the present invention also provides (7) an amino acid sequence represented by SEQ ID NO: 1. To provide a soluble HM1.24 antigen protein.
- the present invention also provides (8) a fusion protein of the soluble HM1.24 antigen protein described in (7) above and another peptide or polypeptide.
- fusion proteins of the soluble HM1.24 antigen protein and other peptides or polypeptides are described in SEQ ID NOs: 3 and 4.
- the present invention further provides (9) a fusion protein of the soluble HM1.24 antigen protein or the soluble HM1.24 antigen protein described in (7) or (8) above and another peptide or polypeptide.
- the DNA encoding the fusion protein of the HM1.24 antigen protein or the soluble HM1.24 antigen protein and another peptide or polypeptide has the sequence shown in SEQ ID NO: 1.
- Other specific examples are the nucleotide sequences shown in SEQ ID NOs: 3 and 4.
- FIG. 1 is a schematic diagram showing the range in which the base sequence of the vector CGM / HA into which the gene expressing the HA tag is inserted has been decoded.
- FIG. 2 is a schematic diagram showing a sandwich ELISA system using an HA-tagged soluble antigen.
- Figure 3 is a graph showing a standard curve of a humanized anti-HM1.24 antibody in a sandwich ELISA system using a culture supernatant of COS-7 cells transiently expressing an HA-tagged soluble antigen. .
- FIG. 4 is a graph showing a standard curve of a humanized anti-HM1.24 antibody in a sandwich ELISA system using a culture supernatant of CH0 cells stably producing a HA-tagged soluble antigen.
- Figure 5 shows the changes in the serum antibody concentration of rhesus monkeys administered chimeric anti-HM1.24 antibody by sandwich ELISA using HA-tagged soluble antigen. It is the graph which showed the measurement result.
- Figure 6 shows that in the sandwich ELISA system using the HA-tagged soluble antigen, the humanized anti-HM1.24 antibody showed the HA of biotin-labeled mouse anti-HM1.24 antibody in the same manner as the chimeric anti-HM1.24 antibody. It is a graph which shows that binding to a tagged soluble antigen is inhibited in a concentration-dependent manner.
- Figure 7 shows that the fluorescence intensity of mouse anti-HM1.24 antibody (left half panel) and anti-HA antibody (right half panel) in FCM analysis using CH0 cells stably producing HA-tagged soluble antigen It is a graph showing that there is a shift as compared to the control antibody (indicated by a dashed line).
- # 1 is the CH0 cell line selected with G418, and #A is the CH0 cell line selected with 5 nM MTX using # 1 cells as the parent line.
- Figure 8 shows that the culture supernatant and the cell lysate from the CH0 cells stably producing the HA-tagged soluble antigen were subjected to SDS-polyacrylamide gel electrophoresis in a reduced state, followed by western blotting using the mouse HM1.24 antibody.
- 17 is a drawing-substitute photograph showing the results of detecting HM1.24 antigen by blotting.
- # 1 is the CH0 cell line selected with G418, #A, #B, and #C are the CH0 cell lines selected with 5 nM MTX using # 1 cells as the parent line, and the KPMM2 cell lysate was HM1 It is a positive control for the .24 antigen.
- Figure 9 shows the results of SDS-polyacrylamide gel electrophoresis of reduced and non-reduced culture supernatants and cell lysates from the CH0 cell #C line that stably produced the HA-tagged soluble antigen.
- 17 is a photograph substituted for a drawing, showing the results of detection of HM1.24 antigen by western blotting using mouse HM1.24 antibody.
- the #C strain is a CH0 cell line selected with 5 nM MTX, and the KPMM2 cell lysate is a positive control for the HM1.24 antigen.
- FIG. 10 is a schematic diagram showing the range in which the nucleotide sequence of the HA-tagged C-terminal deleted soluble HM1.24 antigen expression vector CGM / HA-HM164 was decoded.
- Figure 1i shows the standard curve of a humanized anti-HM1.24 antibody in a sandwich ELISA system using culture supernatant of COS-7 cells expressing soluble HM1.24 antigen with HA-tagged C-terminal deletion.
- FIG. 10 is a schematic diagram showing the range in which the nucleotide sequence of the HA-tagged C-terminal deleted soluble HM1.24 antigen expression vector CGM / HA-HM164 was decoded.
- Figure 1i shows the standard curve of a humanized anti-HM1.24 antibody in a sandwich ELISA system using culture supernatant of COS-7 cells expressing soluble HM1.24 antigen with HA-tagged C-terminal deletion.
- FIG. 10 is a schematic diagram showing the range in which the nucleotide sequence
- Fig. 12 shows the standard curve of humanized anti-HM1.24 antibody in a sandwich ELISA system using culture supernatant of CH 0 cells expressing HA-tagged C-terminal deleted soluble HM1.24 antigen. It is a graph.
- FIG. 13 shows culture supernatants and cell lysates from COS-7 cells or CH0 cells (# 2, # 21, # 28) that produced soluble HM1.24 antigen with HA-tagged C-terminal deletion.
- FIG. 4 presents a photographic diagram showing the result of detecting SDS-polyacrylamide gel electrophoresis in a reduced state and performing western blot with a mouse HM1.24 antibody to detect the HM1.24 antigen.
- CHO / sHM is a CH0 cell expressing HA-tagged soluble HM1.24 antigen, and the culture supernatant is used as a positive control for HM1.24 antigen.
- FIG. 14 is a diagram showing the nucleotide sequence of cDNA encoding the HM1.24 antigen protein and the corresponding amino acid sequence.
- FIG. 15 is a diagram showing the nucleotide sequence of cDNA encoding the HM1.24 antigen protein and the corresponding amino acid sequence.
- FIG. 16 is a schematic diagram of the clone P3.19 isolated using the Panning method and the five clones (IS1 to IS5) isolated by the immunoscreening method.
- FIG. 17 is a diagram showing the results of flow cytometry analysis using an anti-HM-24 antibody (A; CHOZNEO, B; CHO / HM).
- the histogram of the anti-HM1.24 antibody is shown by a solid line, and the histogram of the isotype-matched control antibody (UPC10) is shown by a wavy line.
- the horizontal axis indicates the fluorescence intensity, and the vertical axis indicates the number of cells.
- Figure 18 shows the immunoprecipitation of HM1.24 antigen in various cell lines and HM1.24 expressing CH0 cells using anti-HM1.24 antibody. • A drawing substitute photo showing the results of detection by the Western plotting method. After immunoprecipitation using anti-HM1.24 antibody-conjugated Sepharose 4B (lanes 1 to 6) or unconjugated Sepharose 4B (lanes 7 and 8), Western blotting was performed using the HM1.24 antibody to detect the HM1.24 antigen (shown on the right). (*; Anti-HM1.24 antibody heavy chain)
- FIG. 19 is a graph showing a standard curve of a humanized anti-HM1.24 antibody in the ELISA system using GST-added soluble HM1.24 antigen expressed by Escherichia coli.
- the soluble HM1.24 antigen protein of the present invention includes an amino acid sequence consisting of Asn at the amino acid position 1 to Gin at the amino acid position 132 in the amino acid sequence shown in SEQ ID NO: 1. Any protein may be used as long as it has a amino acid sequence and has the biological activity of the soluble HM1.24 antigen protein.
- the biological activity of the soluble HM1.24 antigen protein is specifically bound to the anti-HM1.24 antibody, is not bound to the cell membrane, is free from the cell membrane, is soluble, and is a dimer. is there.
- the soluble HM1.24 antigen protein of the present invention has the biological activity of the soluble HM1.24 antigen protein, and has one or more amino acids corresponding to the amino acid sequence shown in SEQ ID NO: 1. It may be a soluble HM1.24 antigen protein having an amino acid sequence modified by substitution, deletion and / or addition of amino acid residues. More specifically, the soluble HM1.24 antigen protein of the present invention has the following amino acid sequence as shown in SEQ ID NO: 1 as long as it has the biological activity of the soluble HM1.24 antigen protein. Alternatively, it may have an amino acid substituted with 2 or more, preferably 1 or 24 or less, more preferably 1 or 12 or less amino acid residues.
- amino acid sequence shown in SEQ ID NO: 1 or more preferably 1 or 42 or less, more preferably 1 or 17 or less amino acid residues are deleted. It may have a modified amino acid.
- amino acid sequence shown in SEQ ID NO: 1, 1 or 2 or more preferably 1 or 50 or less, more preferably 1 or 14 or less amino acid residues are added. It may have a modified amino acid.
- the soluble HM-24 antigen protein used in the present invention may also be modified by substitution, deletion and / or addition of the above amino acid at the same time.
- the soluble HM1.24 antigen protein of the present invention comprises an amino acid sequence from amino acid A sn at position 1 to amino acid Arg at position 90 in SEQ ID NO: 1. Or one or more amino acid residues in the amino acid sequence from amino acid A sn at position 1 to amino acid Ar at position 90, substitution, deletion and And / or a soluble HM1.24 antigen protein having an amino acid sequence modified by addition.
- the soluble HM1.24 antigen protein has an amino acid sequence from amino acid Arg at position 90 to amino acid Gin at position 132 in SEQ ID NO: 1 as long as it has the biological activity.
- Soluble HM1 having an amino acid sequence modified by substitution, deletion and Z or addition of one or more amino acid residues with respect to this amino acid sequence. It may be 24 antigen protein.
- Soluble HM1.24 antigen protein having an amino acid sequence modified by substitution, deletion and Z or addition of one or more amino acid residues to the amino acid sequence shown in 1
- the soluble HM1.24 antigen proteins having the amino acid sequences shown in SEQ ID NOs: 3 and 4 I can do it.
- a protein having an amino acid sequence modified by substitution, deletion and / or addition of one or more amino acid residues to a certain amino acid sequence maintains its biological activity (Mark, DF et al., Proc. Natl. Acad. Sci. USA (1984) 81, 5662-5666; Zoller, MJ & Smith, M. Nucleic Acids Research (1982)). 10, 6487-6500, Wang, A. et al., Science 224, 1431-1433, Dalbadie-McFarland, G. et al., Proc. Natl. Acad. Sci. USA (1982) 79, 6409-6413).
- the soluble HM1.24 antigen protein of the present invention may have an amino acid sequence, a molecular weight, an isoelectric point, presence or absence of glycosylation, and glycosylation depending on the species from which it is derived, the host that produces them, and / or the purification method. Position, sugar chain structure, phosphorylation state, and presence or absence of di- or disulfide bond.
- the protein may have any structure as long as it can be suitably used in the present invention. Humans are the preferred species from which proteins are derived.
- Examples of the DNA encoding the soluble HM1.24 antigen protein of the present invention include a base sequence consisting of base adenine at position 1 to base guanine at position 396 of the base sequence shown in SEQ ID NO: 1.
- the DNA encoding the soluble HM1.24 antigen protein of the present invention may be any DNA as long as it has the nucleotide sequence shown in SEQ ID NO: 1.
- Examples of such DNA include dienomic DNA, cDNA, and synthetic DNA. These may be cDNA libraries obtained from various cells, tissues or organs or a species other than human, DNA obtained from the genetic library, or commercially available DNA libraries. It may be a Lee.
- the vector used in these libraries may be any vector such as plasmid, bacteriophage, YAC vector and the like.
- the DNA encoding the soluble HM1.24 antigen protein of the present invention may also be a DNA that hybridizes to the nucleotide sequence shown in SEQ ID NO: 1 and has a biological activity of the soluble HM1.24 antigen protein. It may be a DNA encoding a polypeptide having the same.
- the conditions under which the DNA encoding the soluble HM1.24 antigen protein can hybridize include DNA that hybridizes under appropriate stringency conditions. For example, low stringency conditions can be mentioned.
- Low stringency conditions include, for example, the cleaning conditions provided by 42 ° C, 5X SSC, 0.1% sodium dodecyl sulfate, and 50% formamide. is there. More preferably, high stringency conditions are included.
- high stringency X washing conditions include washing conditions provided by, for example, 60 ° C., 0.1 ⁇ SSC, and 0.1% sodium dodecyl sulfate. It is already known that a protein encoded by a DNA that hybridizes under appropriate conditions to a nucleotide sequence encoding a certain protein has the same biological activity as the protein.
- the soluble HM1.24 antigen protein of the present invention is coded by the above-mentioned "hybridizing DNA", and also includes a protein having the biological activity of the soluble HM1.24 antigen protein.
- SEQ ID NO: 16 The amino acid sequence of the human HM1.24 antigen protein expressed on the cell membrane is shown in SEQ ID NO: 16.
- the soluble HM1.24 antigen protein of the present invention may also be the above protein fused with another peptide or polypeptide as long as it has the biological activity of the soluble HM1.24 antigen protein.
- Known methods can be used for producing these fusion proteins.
- the other peptide or polypeptide to be fused with the protein may be any peptide or polypeptide as long as it is effectively used in the present invention.
- peptides include FLAG (Hopp, T. ⁇ . Et al., BioTechnology (1988) 6, 1204-1210), 6XHis and 10XHis consisting of 6 His (histidine) residues.
- Influenza agglutinin human c-myc fragment, VSV-GP fragment, pl8HIV fragment, T7-tag, HSV-tag, E-tag, SV40T antigen fragment, lck tag, a- Known peptides such as tubulin fragment, B-tag and Protein C fragment are used.
- polypeptides examples include GST (glutathione S-transferase), HA, imnoglobulin constant region, b-galactosidase, MBP (maltose binding protein) and the like. Is mentioned. These can be used commercially available ones.
- the DNA encoding the protein of the present invention can be constructed from the above-described DNA by a commercially available kit using a known method. For example, it can be constructed by digestion with a restriction enzyme, addition of a linker, insertion of an initiation codon (ATG) and / or a termination codon (ATT, TGA or TAG) and the like.
- the expression vector for the protein of the present invention may be any expression vector that is suitably used in the present invention.
- expression vectors include mammalian-derived expression vectors, such as pEF, pCDM8, insect cell-derived expression vectors, such as pBacPAK8, and plant-derived expression vectors.
- Expression vectors such as ⁇ 1, pMH2, animal virus-derived expression vectors, such as pHSV, pMV, yeast-derived expression vectors, such as pNVll, Bacillus subtilis-derived expression vectors, such as pPL608, pKTH50, an expression vector derived from Escherichia coli, for example, pGEX, pGEEX.pMAL p2.
- the protein expression vector of the present invention can be produced by, for example, ligating a DNA encoding a soluble HM1.24 antigen protein downstream of the promoter and introducing it into an expression vector.
- the mouth motor / enhancer is a mammalian promoter
- Enhancers such as EFl- ⁇ promoters, Z enhancers, actin promoters, enhancers from insect viruses, Z enhancers, such as polynuclear (polyhedrin) Viral motor Z-enhancer, plant-derived promoter Z-enhancer-for example, Tanoku's Comozyak virus promoter-Z-enhancer, animal virus-derived promoter Z-enhancer, for example, SV40 motor-Z motor Non-motor, human CMV promoter / enhancer, yeast derived motor / enhancer, e.g., alcohol dehydrogenase promoter Z-enhancer, E. coli-derived promoter Z enhancer, e.g., Lac promoter / enhancer, T rp promo overnight / enhancer, TAC promoter / en The noise is the best.
- Z enhancers such as polynuclear (polyhedrin) Viral motor Z-enhancer, plant-derived promoter Z-enhancer-for example, Tanoku's Com
- a signal sequence suitable for a host used for expression may be added and used.
- the signal sequence include a signal sequence of a secretory protein.
- the signal sequence of the secretory protein include, for example, a signal sequence of a secretory protein derived from a mammal, for example, a signal sequence of an immnoglin.
- the signal sequence of the secretory protein include a signal sequence of a secretory protein derived from E. coli, for example, a periplasmic secretory signal sequence such as OmpA.
- the expression vector thus prepared can be introduced into a host by a known method. Methods for introduction into a host include, for example, electroporation, calcium phosphate method, and ribosome method.
- the protein used in the present invention can be obtained as a recombinant protein produced using a gene recombination technique as described above.
- a recombinant protein is produced by cloning the nucleotide sequence of the gene described herein from a cell, tissue, or organ that expresses the gene, incorporating the clone into an appropriate vector, and introducing this into a host. Let it. In the present invention, this recombinant protein can be used.
- mRNA encoding the gene is isolated from cells, tissues or organs expressing the protein used in the present invention.
- mRNA can be isolated by known methods, for example, guanidine ultracentrifugation (Chirgwin, JM et al., Biochemistry (1979) 18, 5294-5299), AGPC method (Chomczynski, P. and Sacchi, N. , Anal. Biochem. (19 87) 162, 156-159), etc., and purify mRNA from total RNA using mRNA Purification Kit (Pharmacia).
- mRNA can also be directly prepared by using mRNA Purification Kit (Pharmacia).
- the cDNA of the gene is synthesized from the obtained mRNA using reverse transcriptase.
- cDNA can also be synthesized using AMV Reverse Transcri- tase First-strand cDNA Synthesis Kit (Seikagaku Corporation) or the like.
- AMV Reverse Transcri- tase First-strand cDNA Synthesis Kit (Seikagaku Corporation) or the like.
- To synthesize and amplify cDNA the 5'-RACE method (Frohm an, MA et al.) Using Marathon cDNA Amplification kit (manufactured by CLONTECH) and polymerase chain reaction (PCR) was used.
- PCR polymerase chain reaction
- a target DNA fragment is prepared from the obtained PCR product and ligated to the vector-DNA. Furthermore, a recombinant vector is prepared from this, introduced into E. coli, etc., and a colony is selected to prepare a desired recombinant vector.
- the nucleotide sequence of the target DNA is confirmed by a known method, for example, a didoxynucleotide-digestion luminescence method.
- expression can be carried out using a commonly used and useful promoter, a gene to be expressed, a DNA having a polyA signal operably linked to its 3 'downstream, or a vector containing the same. it can.
- a promoter / enhancer human cytomegalovirus immediate early promoter / enhancer can be mentioned.
- other promoters / ennosensors that can be used for protein expression include retrovirus, polymowinores, adenowinores, and simianwinores 40 (SV40).
- Ui Roh-less promoter one / Enha Nsa Ya human E b Nge shea Yo Nfu ⁇ Selector Selector one 1 a may be used promoter Z Enhansa one from mammalian cells (HEF1 a) and the like.
- HEF1 a mammalian cells
- the method of Mulligan et al. (Nature (1979) 277, 108)
- the method of Mizushima et al. Nucleic Acids Res. (1990) 18, 5322.
- promoters include the lacZ promoter and the araB promoter.
- the lacZ promoter the method of Ward et al. (Nature (1098) 341, 544-546; FASEB J. (1992) 6, 2422-2427), and when the araB promoter is used, the method of Better et al. (Science (1988) 240, 1041-1043).
- the pelB signal sequence (Lei, SP, et al J. Bacteriol. (1987) 169, 4379) may be used as a signal sequence for protein secretion when the protein is produced by the periplasm of Escherichia coli.
- the expression vector is used as a selection marker, such as the aminoglycoside phosphotransferase (APH) gene, the thymidine kinase (TK) gene, and the large intestine.
- APH aminoglycoside phosphotransferase
- TK thymidine kinase
- Ecogpt Bacterial xanthinguanine phosphoribosyltransferase
- dhfr dihydrofolate reductase
- any production system can be used for protein production.
- Production systems for protein production include in vitro and in vivo production systems.
- the in vitro production system include a production system using eukaryotic cells and a production system using prokaryotic cells.
- eukaryotic cells there are production systems using animal cells, plant cells, and fungal cells.
- animal cells include (1) mammalian cells such as CH0 (J. Exp. Med.
- CH0 cells include dhfr-CHO (Pro atl. Acad. Sci. USA (1980) 77, 4216-4220) and CHO Kl (Proc. Natl. Acad. Sci. USA (1968) 60, 1275) can be suitably used.
- yeasts such as Saccharomyces and Saccharomyces
- Seschar's Saccharomyces cerev is iae
- filamentous fungi such as Asperglus.
- Aspergillus niger is known.
- prokaryotic cells there are production systems using bacterial cells.
- Escherichia coli (E. coli) and Bacillus subtilis are known as bacterial cells.
- DMEM fetal calf serum
- FCS fetal calf serum
- the pH during culturing is preferably about 6-8. Culture is usually performed at about 30 to 40 ° C. for about 15 to 200 hours, and if necessary, the medium is replaced, aerated, and agitated.
- examples of in vivo production systems include production systems using animals and production systems using plants.
- the desired DNA is introduced into these animals or plants, and proteins are produced and recovered in the animals or plants.
- mice When using animals, there are production systems using mammals and insects. Goats, pigs, sheep, mice, and mice are used as mammals. (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). When using mammals, transgenic animals can be used.
- a DNA of interest is inserted into a gene encoding a protein produced in milk, such as goat / 5 casein, to produce a fusion gene.
- the DNA fragment containing the fusion gene with the inserted DNA is injected into a goat embryo, and the embryo is introduced into a female goat.
- Protein is obtained from the milk produced by the transgenic Zygonia goat born from the goat that has received the embryo or its offspring.
- Hormones may be used in transgenic geese as appropriate to increase the amount of protein-containing milk produced by transgenic geese. (Ebert,.. Et al., Bio / Technology (1994) 12, 699-702).
- silkworms can be used as insects, for example.
- baculovirus into which the target DNA is inserted is infected to the silkworms, and desired protein is obtained from the body fluid of the silkworms (Susumu, M. et al., Nature (1985) 315, 592-594).
- tobacco When using a plant, for example, tobacco can be used.
- the target DNA is introduced into a plant expression vector, for example, ⁇ 530, and this vector is inserted into a vector such as Agrobacterium tumefaciens (Agrobacterium tumefaciens). Introduce to the terrier.
- This bacterium is infected with tobacco, for example, Nicotiana tabacum, to obtain the desired protein from the leaves of the present coconut tree (Julian, K.-C. Ma et al., Eur. J. Immunol (1994) 24, 131-138).
- the gene is introduced into these animals or plants as described above, and proteins are produced and recovered in the animals or plants.
- the protein expressed and produced as described above can be separated from the host inside and outside the cell and from the host and purified to homogeneity.
- the separation and purification of the protein used in the present invention may be carried out by using the separation and purification methods used for ordinary proteins, and is not limited at all.
- chromatographic columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, etc. Proteins can be separated and purified by appropriately selecting and combining (Shinsei Kagaku Experimental Course 1 (1990) Tokyo Chemical Doujin).
- chromatography examples include affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, and the like.
- Adsorption Chromatography —% Strongly Elevated (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marsak et al., Cold Spring Harbor Laboratory Press, 1996) 0 Chromatography can be performed using liquid chromatography such as HPLC and FPLC.
- the concentration of the protein can be measured using a known method. For example, measurement of absorbance or Bradford method may be used.
- the present invention provides a method of detecting or measuring an anti-HM1.24 antibody bound to a soluble HM1.24 antigen protein by reacting a soluble HM1.24 antigen protein with an anti-HM1.24 antibody contained in a test sample.
- HM1.24 antibody Immunochemical measurement method
- the immunochemical measurement method provided in the present invention is performed as an in Vro assay system.
- the atsey system of invitro is performed in a non-cell system. Specifically, a soluble HM1.24 antigen protein is bound to a support, a test sample containing an anti-HM1.24 antibody is added to the protein, the mixture is incubated, washed, and bound to the support. The binding of the anti-HM1.24 antibody to the soluble HM1.24 antigen protein may be detected or measured. Alternatively, specifically, an anti-HM1.24 antibody is bound to a support, a test sample containing a soluble HM1.24 antigen protein is added to this protein, the mixture is incubated, washed, and washed. What is necessary is just to detect or measure the binding of the soluble HM1.24 antigen protein to the anti-HM1.24 antibody bound to.
- Soluble HM1.24 antigen protein or anti-HM1.24 antibody can be obtained from cells that specifically express them, cells transfected with the DNA encoding them, or animals or plants transfected with the DNA encoding them.
- the protein can be used in a purified state or in a partially purified state.
- a purified or partially purified soluble HM1.24 antigen protein or an anti-HM1.24 antibody protein can be used as a support. To be combined. When binding the protein to the support, the protein can be immobilized on the support by a standard method.
- Supports for binding proteins include, for example, insoluble polysaccharides, such as agarose, dextran, cellulose, synthetic resins, such as polystyrene, and polyacrylamide. And silicon.
- beads and plates manufactured using them as raw materials are used.
- a column or the like filled with these may be used.
- a multi-well plate eg, a 96-well multi-well plate
- a biosensor chip can be used.
- the bond between the protein and the support may be a conventional method such as chemical bonding or physical adsorption.
- an antibody that specifically recognizes a protein can be bound to a support in advance by the above-described method, and the antibody can be bound to the protein to bind.
- the binding of the soluble HM1.24 antigen protein and the anti-HM1.24 antibody which can be bound via avidin-Z biotin, is usually performed in a buffer.
- a buffer for example, a phosphate buffer, a Tris buffer, or the like is used. Incubation is performed under conditions that are already commonly used, such as incubation at 4 ° C to room temperature for 1 hour to 24 hours. The post-incubation washing may be any as long as it does not hinder the binding between the soluble HM1.24 antigen protein and the anti-HM1.24 antibody.
- a buffer containing a surfactant is used.
- the surfactant for example, 0.05 ween 20 is used.
- Test samples containing the soluble HM1.24 antigen protein or anti-HM1.24 antibody measured in the present invention include human body fluids (blood, serum, urine, joint fluid, etc.), cell cultures, and the like. Supernatants, animal secretions (milk, etc.), pharmaceutical preparations and the like can be mentioned.
- a control group may be provided together with a group in which the test sample is brought into contact with the protein.
- the control group includes a negative control group containing no test sample or a positive control group containing a purified soluble HM1.24 antigen protein or anti-HM1.24 antibody sample. A group or both groups can be placed.
- the bound protein can be detected by the immunochemical measurement method of the present invention.
- the bound protein can be quantitatively measured.
- the binding between the soluble HM1.24 antigen protein and the anti-HM1.24 antibody can be detected.
- the test sample it is also possible to quantitatively measure the soluble HM1.24 antigen protein or anti-HM1.24 antibody contained in the test sample by obtaining the results of their detection as numerical values and comparing those numerical values. it can.
- the amount of binding between the soluble HM1.24 antigen protein and the anti-HM1.24 antibody can be determined. If the test sample contains soluble HM1.24 antigen protein or anti-HM1.24 antibody, the presence of the bound protein enables detection or detection of soluble HM1.24 antigen protein or anti-HM1.24 antibody. Can be measured.
- soluble HM1.24 antigen protein or It can be quantified based on a standard curve created from numerical values obtained from a positive control group containing a known amount of anti-HM1.24 antibody.
- a biosensor utilizing the surface plasmon resonance phenomenon as a means for detecting or measuring a soluble HM1.24 antigen protein or an anti-HM1.24 antibody in a test sample. It can.
- a biosensor using the surface plasmon resonance phenomenon observes the interaction between proteins in real time as a surface plasmon resonance signal without labeling with a small amount of protein. (Eg, BIAcore; manufactured by Pharmacia). Therefore, it is possible to detect or measure the binding between the soluble HM1.24 antigen protein and the anti-HM1.24 antibody by using a biosensor such as BIAcore.
- a test sample containing an anti-HM1.24 antibody or a soluble HM1.24 antigen protein is brought into contact with a sensor chip on which a soluble HM1.24 antigen protein or an anti-HM1.24 antibody is immobilized, and the soluble HM1 Anti-HM1.24 antibody or soluble HM1.24 antigen protein that binds to the .24 antigen protein or anti-HM1.24 antibody can be detected or measured as a change in resonance signal.
- the sensor chip CM5 Biosensor
- the sensor chip CM5 is activated to immobilize the soluble HM1.24 antigen protein or anti-HM1.24 antibody on the sensor chip. That is, after the sensor chip is activated with an ED CI NHS aqueous solution (200 mM EDC (N-ethyl-N '-(3-dimethylaminopropyoxycarbonate hydrochloride), 50 mM NHS (N-hydroxysuccinimide)), the HBS buffer is activated. Wash the sensor chip with a filter (lOmM HBPES pH 7.4, 150m NaCl, 3.4m MEDTA, 0.053 ⁇ 4 Tween20).
- EDC N-ethyl-N '-(3-dimethylaminopropyoxycarbonate hydrochloride
- NHS N-hydroxysuccinimide
- a test sample containing an appropriate amount of anti-HM1.24 antibody or soluble HM1.24 antigen protein dissolved in HBS buffer is injected.
- the amount of anti-HM1.24 antibody or soluble HM1.24 antigen protein in the test sample bound to the soluble HM1.24 antigen protein or anti-HM1.24 antibody immobilized on the sensor chip was determined by the resonance signal. Observed as an increase in value.
- a control group should be set up together with the group containing the test sample, including a negative control group containing no test sample and a known amount.
- Positive control group containing soluble HM1.24 antigen protein and / or anti-HM1.24 antibody or both groups can be used
- Bound protein should be quantitatively measured as the change in resonance signal value.
- the target protein in the test sample can be detected or measured by comparing the results obtained with the positive control group containing the anti-HM1.24 antibody.
- a soluble HM1.24 antigen protein or an anti-HM1.24 antibody is specifically recognized as a means for detecting or measuring the protein in the bound test sample.
- Primary antibodies can be used.
- a test sample is brought into contact with a soluble HM1.24 antigen protein or an anti-HM1.24 antibody, washed, and the bound protein is detected or measured by a primary antibody that specifically recognizes the protein.
- a primary antibody that specifically recognizes the protein.
- one of the proteins bound to the support is brought into contact with a test sample containing the other protein.
- the cells may be washed, and the bound protein may be detected or measured by a primary antibody that specifically recognizes the protein.
- the primary antibody is preferably labeled with a labeling substance.
- the soluble HM1.24 antigen protein may be fused to other peptides or polypeptides. Therefore, an anti-HM1.24 antibody can be used to detect the soluble HM1.24 antigen protein contained in the test sample, and other peptides or polypeptides fused with the soluble HM1.24 antigen protein can be used. Can be used. Further, in order to detect the anti-HM1.24 antibody contained in the test sample, an antibody that specifically recognizes the anti-HM1.24 antibody can be used. When the anti-HM1.24 antibody is a mouse antibody, an anti-mouse immunoglobulin antibody can be used as an antibody that specifically recognizes the anti-HM1.24 antibody. When the anti-HM1.24 antibody is a chimeric antibody or a humanized antibody, an anti-immunoglobulin antibody can be used as an antibody that specifically recognizes the anti-HM1.24 antibody.
- the protein can be labeled by commonly known methods.
- the labeling substance include a radioisotope, an enzyme, a fluorescent substance, Biotin Z avidin and the like.
- these labeling substances commercially available labeling substances can be used. Is to radioisotopes, for example 3 2 P, 3 3 P, 1 3 ⁇ , '2 5 1, 3 H, 1 4 C, 3 5 S and the like.
- the enzyme include alkaline phosphatase, horseradish spa l-xidase, 3-galactosidase, ⁇ -glucosidase and the like.
- the fluorescent substance include fluorescein isothiocyanate (FITC) and rhodamine.
- HM1.24 antigen protein or an anti-HM1.24 antibody can be obtained commercially and labeled by a known method. Specifically, it can be performed as follows. That is, a solution containing a soluble HM1.24 antigen protein or an anti-HM1.24 antibody is added to a plate, and left overnight to fix it on the plate. When immobilizing the soluble HM1.24 antigen protein or anti-HM1.24 antibody, the antibody for each is fixed on a plate in advance, and the soluble HM1.24 antigen protein or anti-HM 1.24 antibody is immobilized on the immobilized antibody. 24 antibodies may be bound. After washing the plate, block it with, for example, BSA to prevent nonspecific binding of the protein.
- test sample containing the inhibitor After incubation, wash and add antibodies to the test sample. After a suitable incubation, the plate is washed and the protein is detected or measured with a primary antibody that specifically recognizes the protein.
- a primary antibody For detection or measurement, in the case of a radioisotope, detection or measurement is performed by liquid scintillation.
- the substrate In the case of an enzyme, the substrate is added, and the enzymatic change of the substrate, for example, color development is detected or measured by an absorptiometer. In the case of fluorescent substances, detect or measure with a fluorometer. By comparing these results with the values obtained for the control group, the test sample containing the inhibitor can be determined.
- the soluble HM1.24 antigen protein or the anti-HM1.24 antibody in the test sample is detected or measured by using a soluble HM1.24 antigen protein or an anti-HM1.24 antibody.
- a primary antibody that specifically recognizes and a secondary antibody that specifically recognizes the primary antibody can be used.
- the soluble HM1.24 antigen After contacting the test sample with a protein or anti-HM1.24 antibody, incubating, washing and washing, the primary antibody that specifically recognizes the bound protein and the primary antibody specifically recognizes the protein. Detection or measurement using a secondary antibody. That is, specifically, a soluble HM1.24 antigen protein or an anti-HM1.24 antibody is immobilized on a support, and a test sample is contacted. After the incubation, washing is performed, and the bound protein may be detected or measured with a primary antibody that specifically recognizes the protein and a secondary antibody that specifically recognizes the primary antibody.
- the secondary antibody is preferably labeled with a labeling substance. The antibody can be labeled by the above-mentioned method generally known.
- a solution containing soluble HM1.24 antigen protein or anti-HM1.24 antibody is added to the plate, and left overnight to fix it on the plate.
- an antibody against the soluble HM1.24 antigen protein or anti-HM1.24 antibody is immobilized on the plate in advance, and the soluble HM1.24 antigen protein or anti-HM1.24 is immobilized on the immobilized antibody.
- Antibodies may be bound.
- After washing the plate it is blocked with, for example, BSA to prevent non-specific binding of the protein. Wash again and add the test sample to the plate.
- a group without the test sample (negative control) and a group to which Z or a known concentration of anti-HM1.24 antibody or soluble HM1.24 antigen protein was added were placed. Incubate.
- the test sample containing the inhibitor can be determined.
- the soluble HM1.24 antigen protein may be fused to other peptides or polypeptides. Therefore, an anti-HM1.24 antibody can be used as a temporary antibody for detecting the soluble HM1.24 antigen protein contained in the test sample, and fused with the soluble HM1.24 antigen protein. Antibodies to other peptides or polypeptides can also be used. Further, in order to detect the anti-HM1.24 antibody contained in the test sample, an antibody that specifically recognizes the anti-HM1.24 antibody can be used.
- an anti-mouse immunoglobulin antibody can be used as a primary antibody that specifically recognizes the anti-HM1.24 antibody.
- an anti-human immunoglobulin antibody can be used as a primary antibody that specifically recognizes the anti-HM1.24 antibody.
- an antibody that specifically recognizes the primary antibody can be appropriately selected as the secondary antibody. For example, if the primary antibody is a hidge antibody, an anti-hidgymnoglobulin antibody can be used. In addition, when the primary antibody is a rabbit antibody, an anti-psagi immunoglobulin antibody can be used.
- the present invention can be particularly preferably carried out by EL1SA (Enzyme-linked Immunosorbent Assay) as follows. That is, soluble HM1. Antibodies against 24 antigen protein and fused HA (I Nfuru Enza agglutinin) immobilized of buffers over (0. 1 M NaHC0 3 , 0.023 ⁇ 4 NaN 3 , pH 9.6). An appropriate amount of the diluted aqueous solution is added to each well of a 96-well immunoplate (manufactured by Nunc), and the mixture is immobilized at 4 ° C to solidify.
- EL1SA Enzyme-linked Immunosorbent Assay
- washing buffer prepared to be 0.053 ⁇ 4 Tween20 in PBS
- 200 n1 of 5 BSA manufactured by SIGMA
- soluble HM1.24 antigen protein fused with HA diluted with a diluting buffer (1% BSA, 0.5% Tween20, PBS) was added.
- a diluting buffer 1% BSA, 0.5% Tween20, PBS
- After washing three times with a washing buffer add a fixed amount of a test sample containing a chimeric anti-HML24 antibody having a human IgG antibody constant region (C region), and incubate at room temperature for 1 hour.
- wash buffer 100 g of anti-human IgG antibody (1BI) labeled with alkaline phosphatase, diluted 5000 times with dilution buffer, and add 1 well to each well. Incubate for hours. Wash each well 5 times with a washing buffer, and add a coloring solution (substrate buffer: 50 mM NaHCOa, 10 mM MgCl 2 , Sima104 dissolved at a concentration of 1 mg / ml in pH9.8). Add 100 z 1 to each well. After reacting at room temperature, measure the absorbance at 405 nm using a microplate reader (Mode 13550, BI0-RAD). By comparing these results with the values obtained for the negative control group and the Z or positive control group, the chimeric anti-HM1.24 antibody can be detected or measured. Further, it is also possible to detect or measure the soluble HM1.24 antigen protein by the same method.
- the screening method of the present invention can also be used for High Throughput Screening (HTS). Specifically, until pro-rocking The manual reaction is performed, and the subsequent reaction is performed by a robot, thereby realizing a high throughput screenin by automatization.
- HTS High Throughput Screening
- washing buffer prepared with 0.053 ⁇ 4 Tween20 in PBS
- BSA manufactured by SIGMA
- soluble HMl.24 antigen protein fused with HA diluted with dilution buffer (1% BSA, 0.5% Tween20, PBS) and add 4 ° C. Incubate with C to bind the anti-HA antibody and soluble HM1.24 antigen protein fused with HA.
- the immunoplate is set on, for example, a Biomek2000 HTS system (manufactured by Beckman), and the test sample containing the chimeric anti-HM1.24 antibody, the primary antibody against the chimeric anti-HM1.24 antibody, and the primary antibody against the primary antibody are used. Run the system's control program to add the secondary antibody.
- a Biomek 2000 dispenser manufactured by Beckman
- a Multipipette 96-well simultaneous dispenser manufactured by Sagian
- EL404 Microplate Washer Bio Tek
- a SPECTRAmax250 plate reader can be used to measure absorbance.
- the program is set to perform the following operations. That is, each well was washed three times with the washing buffer, and the test sample and the dilution buffer (1% BSA, Add a fixed amount of a test sample containing Chimera anti-HMl.24 antibody diluted with 0.53 ⁇ 4 Tween20, PBS). At the same time, a group not containing the test sample (negative control) and a group to which a chimeric anti-HM1.24 antibody of known concentration was added (positive control) were placed and incubated for 1 hour at room temperature. I do.
- washing buffer add 100 ⁇ g of egret anti-human IgG antiserum (manufactured by New England Blolabs) diluted 5,000-fold with a dilution buffer to each well, and allow to stand at room temperature for 1 hour. Incubate. Wash each well three times with a washing buffer, add 100 liters of anti-mouse IgG antibody (TAG0) labeled with alkaline phosphatase, diluted 1: 5000 in the dilution buffer, and add to each well. And incubate for 1 hour.
- TAG0 anti-mouse IgG antibody
- the immunochemical assay method provided by the present invention can measure soluble HM1.24 antigen protein or anti-HM1.24 antibody up to a concentration of 500 pg / ml.
- a commercially available antibody or an antibody contained in a commercially available kit can be used, or can be obtained as a monoclonal antibody or a polyclonal antibody using known means. .
- Monoclonal antibodies are usually prepared using the desired sensitizing antigen. Immunization according to the above immunization method, fusing the obtained immunocytes with known parent cells by a normal cell fusion method, and screening the monoclonal antibody-producing cells by a normal screening method. Can be manufactured.
- a monoclonal or polyclonal antibody may be prepared as follows.
- the sensitizing antigen from which the antibody is obtained is not limited to the animal species from which it is derived, but the mammal or mammal, for example, human, which is the source of the peptide or polypeptide used in the present invention. Those derived from mice or rats are preferred. Of these, human-derived sensitizing antigens are particularly preferred.
- a human soluble HM1.24 antigen protein when used as a sensitizing antigen, its nucleotide sequence and amino acid sequence can be obtained using the gene sequence disclosed herein. be able to.
- those peptides and polypeptides are chemically converted. They can be synthesized or obtained by genetic engineering techniques.
- the protein, peptide or polypeptide used as a sensitizing antigen may use its full length or its fragment.
- the fragment include a C-terminal fragment and an N-terminal fragment.
- cells expressing the protein, peptide or polypeptide used as the sensitizing antigen can be used as the sensitizing antigen.
- the mammal immunized with the sensitizing antigen is not particularly limited, but is preferably selected in consideration of compatibility with the parent cell used for cell fusion. Bald-toothed, heron, and primate animals are used.
- rodents examples include mice, rats, and hamsters Etc. are used. ⁇ Egrets are used as egrets.
- monkeys are used as primates.
- monkeys with lower nasal nose old world monkeys
- cynomolgus monkeys lizard monkeys
- baboons baboons
- chimpanzees are used.
- Immunization of an animal with a sensitizing antigen is performed according to a known method.
- a sensitizing antigen is administered intraperitoneally or in a mammal.
- the sensitizing antigen is P
- the suspension is mixed with an appropriate amount of an ordinary adjuvant, for example, Freund's complete adjuvant, if necessary, and emulsified, and then administered to the mammal several times every 4 to 21 days.
- an ordinary adjuvant for example, Freund's complete adjuvant, if necessary, and emulsified
- a suitable carrier can be used during immunization of the sensitizing antigen. Immunization is performed in this manner, and an increase in the level of the desired antibody in the serum is confirmed by a conventional method.
- the blood of the mammal sensitized with the antigen is taken out.
- the serum is separated from the blood by a known method.
- a serum containing the polyclonal antibody may be used as the polyclonal antibody, and if necessary, a fraction containing the polyclonal antibody may be further isolated from the serum.
- immune cells may be removed from the mammal and subjected to cell fusion.
- preferred immune cells used for cell fusion include splenocytes, in particular.
- P3 P3X63Ag8.65
- mammalian myeloma cells are already known as mammalian myeloma cells as the other parent cells fused with the immune cells.
- P3 P3X63Ag8.65
- P3X63Ag8.65 Various mammalian cell lines, such as P3 (P3X63Ag8.65), are already known as mammalian myeloma cells as the other parent cells fused with the immune cells.
- P 3 x 63 Ag 8.U 1 Yamamoto, DE et al., Current Topics in Microbiology and Immunology (1978)
- NS-1 Kohler, G. and Mi1stein, C., Eur. J. Im munol. (1976) 6, 511-519
- MPC-11 argulies, DH et al.
- Cell (1976) 8, 405-415 SP 2/0 (Shulman, M. et a 1., Nature (1978) 276, 269-270), F 0 (de St. Groth, SF and Scheidegger, D., J. Immunol.Methods (1980) 35, 1-21), S194 (Trowbridge, IS, J. Exp.Med. (1978) 148, 313-323), R210 (Galfre, G. et al., Nature (1979) 277, 131-133) and the like are preferably used.
- the cell fusion between the immune cells and myeloma cells is basically known, for example, by the method of Milstein et al. (Galfre, G. and Milstein, C. suiods Enzymol. (1981) 73, 3-46). It can be done in accordance with it.
- the cell fusion is performed, for example, in a normal nutrient culture in the presence of a cell fusion promoter.
- a cell fusion promoter for example, polyethylene glycol (PEG), Sendai virus (HVJ) and the like are used, and if necessary, an auxiliary agent such as dimethyl sulfoxide is used to increase the fusion efficiency. You can also.
- the ratio of the use of the immune cells to the myeloma cells is, for example, preferably 1 to 10 times the number of the immune cells to the myeloma cells.
- the culture medium used for the cell fusion include RPMI 1640 culture medium and MEM culture medium suitable for the growth of the myeloma cell line, and other ordinary culture mediums used for this kind of cell culture.
- a culture solution can be used, and a serum sample such as fetal calf serum (FCS) can also be used in combination.
- FCS fetal calf serum
- Cell fusion is performed by mixing a predetermined amount of the immune cells and myeloma cells well in the culture solution, and preliminarily heating to about 37 ° C, for example, a PEG solution.
- a PEG solution having an average molecular weight of about 100 to 600 is usually added at a concentration of 30 to 60% (w / V), and mixed to mix. Is formed. Subsequently, by repeatedly adding an appropriate culture solution and centrifuging to remove the supernatant, the cell fusion agent and the like that are undesirable for the growth of the hybridoma can be removed.
- the hybridoma is selected by culturing it in an ordinary selective culture medium, for example, an HAT culture medium (a culture medium containing hypoxanthine, aminobuterin and thymidine).
- an HAT culture medium a culture medium containing hypoxanthine, aminobuterin and thymidine.
- the culture in the HAT culture solution is continued for a time sufficient for the death of cells other than the target hybridoma (non-fused cells), usually several days to several weeks.
- a conventional limiting dilution method is performed, and screening and cloning of the hybridoma producing the desired antibody are performed.
- human lymphocytes for example, human erythrocyte infected with EB virus
- peptides or polypeptides in vitro.
- a hybrid which produces a desired human antibody having an activity of binding to a lipid (JP-A-63-17688).
- a transgenic animal having a human antibody gene repertoire is immunized with a peptide or polypeptide serving as an antigen, an expression cell thereof, or a lysate thereof to produce antibody-producing cells.
- a human antibody against the peptide or polypeptide used in the present invention may be obtained using a hybridoma obtained by fusing it with myeloma cells (International Patent Application Publication No. WO 9 2-0 3 9 18, WO 9 3 — 2 2 7, WO 94-0 2 6 0 2, W094-2 5 5 8 5, WO 9 6-3 3 7
- the hybridoma producing the monoclonal antibody thus produced can be subcultured in a normal culture solution, and can be stored for a long time in liquid nitrogen.
- a method of culturing the hybridoma according to a usual method and obtaining the culture supernatant, or a method of obtaining a hybridoma compatible mammal A method is used in which the cells are transplanted into a plant, proliferated, and obtained as ascites.
- the former method is suitable for obtaining high-purity antibodies, while the latter method is suitable for mass production of antibodies.
- cells in which immune cells such as sensitized lymphocytes producing antibodies are immortalized by oncogenes may be used.
- the monoclonal antibody thus obtained can also be obtained as a recombinant antibody produced using a gene recombination technique.
- a recombinant antibody is produced by cloning an antibody gene from an immune cell such as a hybridoma or a sensitized lymphocyte producing the antibody, incorporating the clone into an appropriate vector, and introducing it into a host.
- This recombinant antibody can be used in the present invention (for example, Borrebaeck, C.A.K. and Larrick, J.W., THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). See).
- the antibody used in the present invention may be an antibody fragment or a modified antibody as long as it has a desired binding activity.
- the antibody fragment includes Fab, F (ab ') 2, Fv, or single-glutinin FV (scFV) in which the Fv of H chain and L chain are linked by an appropriate linker.
- enzymes such as papine and pepsin Antibody fragments, or constructing a gene encoding these antibody fragments, introducing this into an expression vector, and then expressing it in a suitable host cell (for example, Co, MS et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, AH, Methods Enzymol.
- the antibody detected or measured by the immunochemical assay method of the present invention may be any of the above-mentioned antibodies, for example, any of antibodies produced by hybridomas, recombinant antibodies, chimeric antibodies, and humanized antibodies. May be.
- the antibody expressed and produced as described above can be separated from the host inside and outside the cell and from the host and purified to homogeneity.
- the separation and purification of the antibody used in the present invention may be performed by the separation and purification methods used for ordinary proteins, and is not limited at all.
- chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, etc. selection, combination lever, antibody can be separated and purified (antibodies:. a Labora tory Manual Ed Harlow and David Lane, Cold Spring Harbor La boratory, 1988) 0
- Columns used for affinity chromatography include a protein A column and a protein G column.
- a protein A column For example, as a column using a tin tin A column, Hyper D, POROS, Sephar ose FF (Pharmacia) and the like.
- Chromatography other than affinity chromatography includes, for example, ion-exchange chromatography, hydrophobic chromatography, gel filtration, reversed-phase chromatography, and adsorption chromatography. Rafie (Strategies for Protein Purification and Character ization: A Laboratory Course Manual. Ed Daniel R. arshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographies can be carried out using liquid chromatography such as HPLC, FPLC and the like.
- ELISA Enzyme immunoassay
- RIA radioimmunoassay
- fluorescent antibody method For measuring the concentration or confirming the activity of the antibody obtained above, known methods, for example, ELISA, EIA (enzyme immunoassay), RIA (radioimmunoassay) or fluorescent antibody method can be used.
- Hypri-Doma HM1.24 which produces anti-HM1.24 antibody, was supplied to the Institute of Life Science and Technology, National Institute of Advanced Industrial Science and Technology (1-1-3 Tsukuba-Higashi, Ibaraki Pref.) In September 1995. Deposited internationally on the 14th as FERM BP-5233 under the Budapest Treaty.
- Example 1 Construction of FLAG-tagged soluble HM1.24 antigen expression vector HEF expression vector prepared by digestion with EcoRI (Takara Shuzo) and Notl (Takara Shuzo) (International Patent Application Publication No. W092-19759) ) And a gene pair encoding a system ij and FLAG tag (supplied by Sudi Technology Co., Ltd.) with 50 mM Tris-HC1, pH 7.6, 10 mM MgCl 2 , 10 mM Incubate at 16 ° C for 3 hours in a reaction mixture containing dithiothrate, 1 mM TP, 50 mg zoml of polyethylene glycol and 1 unit of T4 DNA ligase (GI BC0-BRL). Connected.
- the genes encoding the inserted Ig leader sequence and FLAG tag are EcoRI, Kpnl (Takara Shuzo) and the synthetic gene pair shown in SEQ ID NO: 12 and 13 in which the Not 1 restriction enzyme recognition site is connected as a linker.
- the ligation reaction mixture was added to Escherichia coli DH5a competent cells (GIBCO-BRL), which was allowed to stand on ice for 30 minutes, at 42 ° C for 1 minute, and again on ice for 1 minute.
- the gene in the extracellular region of the HM1.24 antigen was amplified by PCR using a Thermal Cycler (Perk in Elmer Cetus).
- a Thermal Cycler Perk in Elmer Cetus
- the primers shown in SEQ ID NOS: 9 to 10 at 100 pmole, 10 mM Tris-HCl, pH 8.3, 50 mKC1, 0.1 mM dNTPs (dATP, dGTP, dCTP , dTTP), 1.5 mM MgCl 2 and 5 units of DNA polymerase Ampli Taq (Perkin Elmer Cetus) were first denatured at 94 ° C, followed by denaturation at 94 ° C.
- This plasmid DNA was designated as FLAG-tagged soluble antigen expression plasmid and named pSFHMl.24.
- the nucleotide sequence was determined using an automatic DNA sequencer (Applied Biosystem In) and a Taq Dye terminat or Cycle Sequencing kit (Applied Biosystem In) according to the protocol specified by the manufacturer. As a result, the structure was confirmed to express a fusion protein (SEQ ID NO: 2) in which a FLAG tag peptide was linked to a soluble antigen.
- the HA-tagged soluble antigen expression plasmid was constructed using the FLAG-tagged soluble HM1.24 antigen expression vector.
- the B1 uescr ipt SK-vector-1 (Molecu lar Cloning: A Laboratory Manual, Sambrook et al.) Containing the Cytomegalovirus (CMV) promoter / enhancer, neomycin resistance gene, Dehydroiolate reductase (DHFR) gene and leader sequence. Cold Spring Harbor Laboratory Press, (1989)) (The gene coding for the epitop tag of Komamag and Noretinin was inserted.
- CMV Cytomegalovirus
- DHFR Dehydroiolate reductase
- hemagglutinin epitop tag amino acid sequence: YPYDVPDYA
- a synthetic DNA pair manufactured by Cymedia connected with DraIII and Kpnl restriction enzyme recognition sites as linkers (SEQ ID NO: 14 and 15).
- a 5 -g vector prepared by digesting the gene pairs HA-S and HA-R encoding hemagglutinin epitopags of 500 pmo1 each with Kpnl and DraIII (Takara Shuzo).
- DNA ligation kit Ver.2 (Takara Shuzo) in a reaction mixed solution containing 5 ⁇ 1 solution at 16 ° C for 1 hour and ligated.
- This Escherichia coli was seeded on Manual, Sambrook, Cold Spring Harbor Laboratory Press, (1989)) and incubated at 37 ° C overnight to obtain an E. coli transformant.
- the soluble HM1.24 antigen gene (sHM) to be used was obtained from pSFHMl.24.
- a soluble antigen was prepared by purifying a 410 bp fragment from a reaction mixture obtained by digesting pSFHMl.24 with Kpnl and BamHI using agarose gel (manufactured by SIGMA).
- sHM was introduced into CGM / HA.
- anti-smut containing 50m Tris-HCl, pH 9.0, 1m MgCl 2 and 2 units of alkaline phosphatase (E. coli C75) (Takara Shuzo)
- the mixture was reacted at 65 ° C for 15 minutes in the reaction mixture to perform dephosphorylation.
- 100 ng of the dephosphorylated CGM / HA and sHM were ligated by reacting at 16 ° C for 1 hour in a reaction mixture solution containing 5 ⁇ l of DNA ligation kit Ver.2 (Takara Shuzo) I solution.
- the 1 ⁇ 1 ligation mixture was added to 100 n1 of E. coli JM109 competent cells (manufactured by Nippon Gene), and the mixture was added on ice for 30 minutes, at 42 ° C for 1 minute, and again on ice for 1 minute. It was left still. Then, calorie the 4001 S0C medium (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, (1989)), incubate at 37 ° C for 1 hour, and then add 50 mg / ml.
- the Escherichia coli was inoculated on a 2xYT agar medium (Molecular Cloning: A Laboratory Manual, Sambrook, Cold Spring Harbor Laboratory Press, (1989)) containing ampicillin and incubated at 37 ° C overnight. E. coli transformants were obtained.
- This E. coli transformant was incubated at 37 ° C in 600 ml of LB medium containing 100 ng / ml ampicillin (Molecular Cloning: A Laboratory Manual, Sambrook et al., Co Id Spring Harbor Laboratory Press, (1989)). Then, plasmid DNA was prepared from the culture according to the alkaline method (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, (1989)). The thus prepared plasmid containing the gene encoding the hemagglutinin epitope tag and the gene encoding the soluble HM1.24 antigen was named CGM / HA-sHM, and the HA tag The added soluble HM1.24 antigen expression plasmid was used.
- the nucleotide sequence of a plasmid (CGM / HA) containing the gene encoding the hemagglutinin epitop tag was determined using an automated DNA sequencer (Applied Biosystern Inc.) and Taq Dye terminator Cycle Sequencing kit. (Applied Biosystem Inc.) according to the protocol specified by the manufacturer.
- the primers used in the reaction are shown in SEQ ID NOs: 7 to 8, the range of the decoded base sequence is shown in FIG. 1, and the determined base sequence is shown in SEQ ID NO: 5. This confirmed that the sequence matched the theoretical sequence.
- the expression vector (CGM / HA-sHM) was tested in COS-7 cells (ATCC # CRL-1651). Cotransformation of C0S-7 cells by electroreaction using a Pulser device (Bio-Rad) Changed.
- the expression plasmid (1 ⁇ g) was added to a 0.8 ml aliquot of 1.1 ⁇ 10 7 cells / ml in PBS and pulsed at 1.5 kV, 25 F volume.
- the electroporated cells were suspended in 10 ml of DME culture medium (GIBCO-BRL) containing 10% fetal calf serum (GIBCO-BRL). They were cultured at 37 ° C, 5% C0 2 Lee Nkyu base one coater. After culturing for 6 days, the culture supernatant was collected, cell debris was removed by centrifugation, filtered with a 0.22 // m filter (MILLIP0RE), and stored at 4 ° C.
- DME culture medium GEBCO-BRL
- fetal calf serum GEBCO-BRL
- CH0 cell strain DG44 (Urlaub, G et al., Cell (1983) 33 (2) 405-412) was used as a host cell. Since the DG44 strain is a DHFR-deficient strain, it shows auxotrophy for glycine, prin nucleotide and thymidine. Then, when the plasmid expressing the neomycin resistance gene and DHFR is transfected, DHFR +, neomycin resistant transformed cells are selected using a G418-supplemented nucleoside-deficient medium. I can do it. Furthermore, selection was made by gradually increasing the concentration of methotrexate (MTX), an inhibitor of DHFR, in the medium, and the surviving cells were amplified in the copy number of the introduced expression plasmid. The production of the target product increases.
- MTX methotrexate
- the clone # 1 selected by G418 was further suspended in a CHO-S-SFM II culture solution containing no nucleotides and supplemented with 5 n MTX (manufactured by SIGMA), and 5 x 10 2 cells / wel K
- the cells were seeded in a 96-well flat-bottom plate at 100 1 / well at a concentration of 3 at 5 ⁇ 10 3 cells / welK 5 ⁇ 10 4 ce 11 s / we 11. After incubation overnight at 37 ° C, 5% C0 2 Lee Nkyubeta one, a 5 nM MTX added CHO- S-SF Mil selection medium was added 100 u 1 / well.
- HM1.24 antigen purified from this culture supernatant can be used for searching for HM1.24 ligand or for functional analysis of HM1.24 antigen.
- a preliminary study of the ELISA system was performed using the culture supernatant of COS-7 cells.
- an anti-HA antibody control an anti-1L-6 receptor antibody MT18 antibody (mouse IgG2bk ⁇ (Hirata, Y et al., J. Immunol. (1989) 143 (9) 2900-2906)) was used. used.
- the control of the chimeric anti-HM1.24 antibody includes human IgGl (human IgGl kappa purified, manufactured by THE BINDING SITE) derived from Mie's mouth as well as the chimeric antibody. Antibody purified with a Tin A column) was used.
- Anti-HA antibody (mouse monoclonal antibody: Clone 12CA5, manufactured by Boehringer Mannheim) and B. (Coating Buffer: 0.1 g / ml and 5 g / ml) M NaHCO 3, buffer, pH 9.6, was prepared with 0.02% azide Na Application Benefits um), 100 1 / well in flat-bottomed 96 Anapu rate (Immuno plate I with test: manufactured by Nunc) to 4. Coated with C. After washing three times with RB (Rinse Buffer: PBS, 0.05% Tween 20), at 200 1 / well! B.
- the reaction was added at 100 1 / well at room temperature for 1 hour. After washing 5 times with R.B., S1GMA104 was similarly added to develop color, and the absorbance at 405 nm to 655 nm was measured.
- FIG. 2 schematically shows a sandwich E / SA system using the HA-added soluble HMl.24 antigen.
- a sandwich ELISA was performed in the same manner as for the culture supernatant of COS-7 cells. However, the soluble antigen was reacted at 4 ° C for intense reaction, and AHM was diluted three-fold from 1 ⁇ g / ml.
- the standard curve when using soluble antigens from CH0 cells was as shown in Fig. 4.
- the measurement limit was about several ng / ml.
- the amount of soluble antigen produced was compared by anti-HA antibody, sandwich ELISA using chimeric anti-HM1.24 antibody and humanized anti-HM1.24 antibody, and cell line selection was performed. went.
- the culture supernatant of the HA-tagged soluble antigen-producing cells was serially diluted and added. Since the purified antigen has not been obtained, the antigen concentration cannot be determined. For comparison, the culture supernatant obtained by culturing the cells for 4 days with the same initial seeding amount was used.
- chimeric anti-HM1.24 antibody and humanized anti-HM1.24 antibody were added, and the mixture was incubated at room temperature for 1 hour.
- Alkaline phosphatase-labeled goat anti-human IgG (manufactured by BI0S0URCE) was added, and the mixture was allowed to react at room temperature for 1 hour. Then, the base solution was added. The color was developed at room temperature, and the absorbance at 405 nm to 655 nm was measured with a mi croplate reader model 3550 (manufactured by BIORAD).
- clone # 1 was selected with G418, and this was amplified with 5 nM MTX (manufactured by SIGMA) as a parent strain to obtain, #B and #C.
- the chimera-type anti-HM1.24 antibody was administered at a dose of 4 mg / kg or 40 mg / kg, and blood was collected from macaques treated with v. Infusion before, on days 1, 3, 7, and 14 after administration, and 4 ° C. Centrifugation under C gave serum.
- blood was similarly collected from rhesus monkeys to which physiological saline was administered instead of the chimera-type anti-HM1.24 antibody to obtain serum.
- the concentration of the chimera-type anti-HM1.24 antibody in the serum was measured by a sandwich ELISA using an HA-tagged HM1.24 soluble antigen.
- HM1.24 soluble antigen diluted 4-fold culture supernatant from CH0 cells.
- the serum of rhesus monkeys to which the chimera-type anti-HM1.24 antibody was administered was serially diluted and added to each well in an amount of 100 ⁇ l / well.
- the chimera-type anti-HM1.24 antibody used for administration as a standard was serially diluted from 10 / ml into a three-fold dilution in 11 steps and used. After 1 hour incubation and washing at room temperature Then, an alkaline phosphatase-labeled goat anti-human IgG antibody (manufactured by BI0S0URCE) was added.
- the binding inhibitory activity of the human anti-HM1.24 antibody by the biotin-labeled mouse anti-HM1.24 antibody was measured by sandwich ELISA using HA-tagged HM1.24 soluble antigen. Block the plate coated with anti-HA antibody at 1 ⁇ g / ml and add HA-tagged HM1.24 soluble antigen (diluted 4-fold culture supernatant from CH0 cells) at 100 1 / well. The reaction was carried out at 4 ° C overnight.
- human anti-HM1.24 antibody and chimeric anti-HM1.24 antibody are serially diluted from 10 g / ml into three-fold dilutions in three-fold dilutions, and added 50/1 to each well, and 20 ng at the same time A 50 / ml biotin-labeled mouse anti-HM1.24 antibody was also added, and reacted at room temperature for 1 hour.
- HA-added soluble HM1.24 antigen-producing CH0 cells did not produce much antigen.
- FCM flow cytometry
- mice IgG2ak (UPC10) (CAPPEL) 51 and FACS buffer 951 instead of mouse anti-HM1.24 antibody, or mouse lgG2bk antibody (MT18) instead of anti-HA antibody 5 ⁇ 1 and 95 951 of FACS buffer were added, and the mixture was incubated similarly.
- 100 ⁇ l of a 10 / g / ml FITC-labeled goat anti-mouse IgG antibody (manufactured by Becton Dickinson) was added, and the mixture was incubated at an ice temperature for 30 minutes.
- the cells were suspended in 600-1 FACS buffer and the fluorescence intensity of each cell was measured by FACScan (manufactured by Becton Dickinson).
- a cell lysate was similarly prepared for 1.0 ⁇ 10 7 KPMM2 cells (Patent Application Publication No. JP-A-7-236475).
- the number of cells corresponding to the culture supernatant 20 ⁇ 1 (# 1: 3 X 10 4 cells, # ⁇ : 4 X 10 4 cells, # ⁇ : 3 ⁇ 10 4 pieces, #C: 2.8 x 10 4 cells) of To the cell lysate 101 containing the same, 51 of a sample buffer containing 5% 2-mercaptoethanol was added, and the mixture was heated at 100 ° C for 5 minutes.
- KPMM2 cell lysate which is a myeloma cell that overexpresses HM1.24 antigen instead of culture supernatant, etc. as a positive control (1 x 10 5 cells) 10 ⁇ 1 to 5!
- sample buffer 10 ⁇ 1 of sample buffer was added to the culture supernatant #C of 2 ⁇ 1, and the mixture was heated at 100 ° C for 5 minutes. Further, the sample of buffers over to cell dissolve was 10 / I of #C containing four 2.8 X 10 5 fi 1 added, 100. Heated at C for 5 minutes. Sample buffer was added to KPMM2 cell lysate (1 x 10 5 cells) 10 ⁇ 1, which is a myeloma cell that overexpresses HM1.24 antigen instead of culture supernatant as a positive control. ⁇ Add 1 and heat in the same way
- the HM1.24 antigen since the HM1.24 antigen also has a hydrophobic region of about 14 amino acids on the C-terminal side, a part of the expressed antigen is not secreted into the culture supernatant as a soluble form. It was thought to remain on the cell surface. Therefore, hereinafter, the HA-tagged soluble antigen from which the N-terminus including the N-terminal transmembrane region has been deleted and the HA-tagged soluble antigen from which the C-terminus including the C-terminal hydrophobic region has been deleted are further described. Produced.
- This PCR product was digested with Kpnl and BamHl as a soluble antigen (HM164) from which the C-terminus was also deleted, and 5 ⁇ g of vector (CGM / HA) prepared by digestion with Kpnl and BamHI was added to the PCR product.
- Reaction mixture containing mM Tris-HC1, pH 7.6, 10 mM MgCh, 10 mM dithiothreitol, 1 mM ATP, 50 mg / ml polyethylene glycol and 1 unit T4 DNA ligase (GIBC0-BRL) The reaction was carried out at 16 ° C for 3 hours in the medium.
- E. coli JM109 competent cells Toyobo 100a1
- the cells were placed on ice for 30 minutes, at 42 ° C for 1 minute, and again on ice for 1 minute. It was left still.
- 400 1 SO Medium C Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, (1989)
- After incubation for 1 hour at C place on an LB agar medium containing 50 ⁇ g / ml ampicillin (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, (1989)).
- the Escherichia coli was inoculated and incubated at 37 ° C overnight to obtain an Escherichia coli transformant.
- This transformant was incubated in 3 ml of LB medium (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, (1989)) containing 50 g / ml of ampicillin. After culturing overnight at C, plasmid DNA was prepared from this culture according to the alkaline method. After digesting this plasmid DNA with Kpnl and BamHI, a 360 bp plasmid was selected by 1% agarose gel electrophoresis, and the selected transformant was transformed into LB medium containing 50 ⁇ g / ml ampicillin. Cultured overnight at 37 ° C in 0 ml.
- Plasmid DNA was prepared from this culture by the alkaline method (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, (1989)), and the hydrophobic region at the C-terminus was deleted. It was named (CGM / HA-HM164) as a plasmid expressing HA-tagged soluble antigen.
- the nucleotide sequence of plasmid (CGM / HA-HM164) expressing HA-added soluble antigen with the C-terminal hydrophobic region deleted was determined.
- the above expression plasmid was digested with Bgl II (Takara Shuzo).
- Bgl II Takara Shuzo
- the nucleotide sequence was determined according to the protocol specified by the manufacturer.
- the primers used for the reaction were set forth in SEQ ID NOS: 9 and 11, and the The box is shown in FIG. 10 and the determined nucleotide sequence is shown in SEQ ID NO: 6. This confirmed that the sequence matched the theoretical nucleotide sequence.
- the expression plasmid CGM / HA-HM164 was purified by the electrophoresis method as described above (see Example 4. The gene was simultaneously transfected into COS-7 cells under the conditions of (transfection into 7 cells). Further, the cells subjected to the electroporation treatment were cultured under the same conditions as described above (Example 4) for 6 days, and the collected culture supernatant was applied to a 0.22 / m filter (manufactured by ILLIP0RE). Stored at 4 ° C.
- G418 (GIBC0 BRL) was selected.
- Example 17 Sandwich ELISA using culture supernatant
- Example 7 sandwich ELISA using culture supernatant.
- the culture supernatant of C0S-7 cells and CH0 cells diluted 4 times was removed.
- the solution was added at 100 ⁇ 1 / well, and reacted at 4 ° C.
- serial dilution of 1 g / ml of humanized anti-HM1.24 antibody was performed by 3-fold dilution. 100 n 1 / well was added to the wells, and the mixture was allowed to react at room temperature for 1 hour.
- a 5000-fold diluted alkaline phospho-labeled goat anti-human IgG (manufactured by BI0S0URCB) was reacted for 1 hour at room temperature. After washing, the substrate solution was added, and the absorbance at 405 nm to 655 nm was measured with a Microplate reader (manufactured by BI0RAD).
- the production amount of soluble antigen was compared by sandwich EUSA using anti-HA antibody and chimeric anti-HM1.24 antibody, and cell lines were selected. After plating a plate coated with anti-HA antibody at 1 ⁇ g / ml, the culture supernatant of the HA-tagged soluble antigen-producing cells was serially diluted and added. Since the purified antigen was not obtained, the antigen concentration was not known. To compare the concentrations, we used the culture supernatant in which cells were cultured for 4 days with the same initial seeding volume.
- Example l Western blotting First, a cell lysate was prepared. HA-tagged C-terminal to express deleted soluble antigen, 1 X 10 7 cells of COS- 7 cells and 4 click loans of HA-tagged C-terminal deleted soluble antigen expression CH0 cells selected in G418 ( # 1: 1.2 X 10 7 cells, # 2: 1.5 xlO 7 cells, # 21: 2.2 x 10 7 cells, # 28: 1.3 xlO 7 cells), respectively, under the conditions of Example 12 described above.
- # 1 1.2 X 10 7 cells, # 2: 1.5 xlO 7 cells, # 21: 2.2 x 10 7 cells, # 28: 1.3 xlO 7 cells
- culture supernatant (COS-7 Sup., CHO Sup. # 2, # 21, # 28) from which cells were cultured was passed through a 0.22 ⁇ m filter at 4 ° C. Saved in C.
- Sample buffer containing 5% 2-mercaptoethanol in this culture supernatant 201 (0.5 M Tris-HCl buffer containing 10% glycerol, 2% SDS, 0.253 ⁇ 4 bromphenol blue, pH 6. 8) was added and heated at 100 ° C for 5 minutes.
- cell lysate (COS-7: 1 ⁇ 10 5 cells, # 2: 5.4 ⁇ 10 4 , # 21: 1 ⁇ 10 6) cell number of 10 to 16 times the number of cells corresponding to the culture supernatant 20 II 1 s , # 28: 5 n 1 of sample buffer containing 5% 2-mercaptoethanol was added to 10/1 of the cell lysate containing 5.9 x 10 4 ), and the mixture was heated in the same manner.
- FIG. 13 shows the results of western blotting of these with the mouse anti-HM1.24 antibody under the conditions described above (Example 13.).
- soluble HM1.24 antigen was detected in the culture supernatant as in the previous case, but the cell lysate of the soluble C-terminally deleted soluble antigen-producing cell prepared this time contained HM1.24 antigen. No expression was seen.
- the HA-added soluble HM1.24 antigen trapped on the cell surface became secreted into the culture supernatant.
- the soluble C-terminally deleted antigen also formed a homodimer.Example 20.
- the Escherichia coli was collected, suspended in D-PBS (-), frozen and stored at 180 ° C., and the expressed GST.IS-1 used for the following purification was extracted from the Escherichia coli inclusion body. That is, after the thawed E. coli was thawed, Tron X100 was added thereto to a concentration of 1%, and the mixture was sonicated for 1 minute using a Branson Sonifier 250 under the conditions of output 2 and duty 50%. The precipitate fraction was collected by centrifugation at 14000 rpm for 20 minutes using Tomy MX160.
- This precipitate fraction was suspended in a 50 mmol / L Tris-HCl buffer containing 100 ug / mL Lysozyme, pH 8.0, and quenched under ice cooling for 30 minutes. After the Lysozyme digestion, MgCl 2 was added at a concentration of 5 mmol / digest, followed by digestion with DNase I at room temperature for 10 minutes. The precipitate was collected by centrifugation at 14000 rpm for 20 minutes, and washed twice with 50 ⁇ 1 / L Tris-HCl buffer containing 1% Triton X100, pH 8.0.
- the GST. IS-1 extract was purified by anion exchange using DEAE Sepharose Fast Flow.
- the GST. IS-1 extract was added to a column of DEAE Sepha rose Fast Flow equilibrated with 50 mmol / L Tris-HCl buffer containing 8 moi / L Urea, 10 mmol / L DTT, pH 8.0, and the same. The plate was washed with a buffer. The adsorbed GST. IS-1 was eluted by adjusting the concentration of NaCl to 0.25 mol / L, and this fraction was designated as GST. IS-1 (D).
- GST • IS-1 (D) was purified by reversed-phase HPLC using C0SM0SIL C4.
- GSTIS-1 (D) is diluted with twice the volume of 200 mmol / L sodium acetate-HC1 buffer, pH 3.5, and equilibrated with 20 nnnol / L sodium acetate-HCl buffer, pH 3.5. It was desalted with a -10 column.
- an equal volume of 0.1% TFA was added to the desalted GST • IS-1 (D) and adsorbed on C0SM0SIL C4 equilibrated with 20% CH 3 CN / 0.1% TFA.
- the adsorbed GST.IS-1 was eluted by linearly increasing the concentration of acetonitrile to 60%.
- the major GST. IS-1 eluted fraction was named GST-IS-1 (C4) o
- GST • IS-1 (C4) was purified by a second reversed-phase HPLC using Vydac Diphenyl.
- GST • IS-1 (C4) was diluted three times with deionized water and adsorbed on Vydac Diphenyl equilibrated with 30% CH 3 CN / 0.1% TFA. The adsorbed GST. IS-1 was eluted by linearly increasing the concentration of acetonitrile to 60%. GST.1S-1 eluted as the main peak.
- Coating Buffer is 100 mmol / L NaHCO 3 solvent solution containing 0.02% Na 3
- Dilution Buffer ( DB) is 1 mmol / L gCl 2)
- 150 discussions 1 / and NaCl, 0. 05% Tween20, 0.02 % NaN 3 50 mmol / L Tris-HCl, pH 8.1 containing 1% BSA
- Substrate Buffer (SB) contains 50 mmol containing lOmmoi / L MgCl 2 / L NaHCO 3, pH 9.8 solution, the 0.1% Tween 20 / TBS were used TBS (TaKaRa CodeT903 Lot201) containing 0. 1% T een 20. GST.
- IS-1 (D) was directly immobilized on Nunc Immuno Plate axi Sorp, and the concentration of the human anti-HM1.24 antibody was measured. GST. IS-1 (D) was diluted with CB, added to Nunc Immuno Plate Maxi Sorp at 100 1 / well, and immobilized at room temperature for 1 hour. After washing 3 times with 200% 1 / wel 1 using 0.1% Tween20 / TBS, DB was added with 2001 Zwell and blocking was performed at room temperature for 1 hour or more. As a test substance, a human anti-HM1.24 antibody diluted with DB was reacted at 100 ⁇ l / well at room temperature for 1 hour.
- the alkaline phosphatase-labeled goat anti-IgG (Goat ant i human IgG rchain AP con juga te) (Biosource AH20305 Lot 6202) was reacted in a 100 ⁇ l well for 1 hour at room temperature.
- Sigmal04 adjusted to 1 mg / ml with SB was added with 100l Zwell, and the color was developed for 1 hour at room temperature.
- the absorbance at 405 nm-620 nm was measured with Bio-Rad Mode 13550. As a result, a concentration-dependent increase in absorbance of the humanized anti-HM1.24 antibody was obtained (FIG. 19).
- a mouse anti-HM1.24 monoclonal antibody-producing hybridoma was prepared according to the method described in Goto, T. et al., Blood (1994) 84, 1992-1930.
- the antibody in the culture supernatant of the hybridoma was screened using Cell BLISA using KPC-32 (Posner, MR et al., J. Immunol. Ethods (1982) 48, 23). 5 ⁇ 10 4 KPC-32 were suspended in 50 ml of PBS, dispensed into a 96-well plate (U-bottom type, manufactured by Corning, Iwaki), and air-dried at 37 ° C. After blocking with PBS containing 1% serum albumin (BSA), the hybridoma culture supernatant was added, and the mixture was incubated at 4 ° C for 2 hours.
- KPC-32 Posner, MR et al., J. Immunol. Ethods (1982) 48, 23. 5 ⁇ 10 4 KPC-32 were suspended in 50 ml of PBS, dispensed into a 96-well plate (U-bottom type, manufactured by Corning, Iwaki), and air-dried at 37
- a peroxidase-labeled anti-mouse IgG goat antibody (manufactured by Zymed) was reacted at 4 ° C for 1 hour. After washing, a 0-phenylenediamine substrate solution (manufactured by Sumitomo Bakelite) was added at room temperature for 30 minutes. It was allowed to react.
- the reaction was stopped with 2N sulfuric acid, and the absorbance at 492 nm was measured using an ELISA reader (manufactured by Bio-Rad).
- ELISA reader manufactured by Bio-Rad.
- the positive hybridoma culture supernatant was pre-adsorbed to human serum, and the reactivity to other cell lines was screened by ELISA. Positive hybridomas were selected and their reactivity to various cells was determined by flow cytometry.
- the last selected hybridoma clone was cloned twice and injected into the abdominal cavity of pristane-treated BALB / C mice to obtain ascites.
- Monoclonal antibodies were purified from mouse ascites by precipitation with ammonium sulfate and protein A affinity chromatography kit (Ampure PA, manufactured by Amersham). Purified antibody, Quick Tag FI FITC labeling was performed by using a TC binding kit (manufactured by Boehringer Mannheim).
- HM1.24 a hybridoma clone most useful for flow-site analysis and having CDC activity against RPMI 8226 was selected and named HM1.24.
- the subclass of the monoclonal antibody produced by this hybridoma was determined by ELISA using a subclass-specific anti-mouse porcupine antibody (Zymed).
- the anti-HM1.24 antibody had a subclass of IgG2a / c.
- Hypri-Doma HM1.24 which produces anti-HM1.24 antibody, was submitted to the Institute of Biotechnology, Institute of Industrial Science and Technology (1-3 1-3 Tsukuba East, Ibaraki Prefecture) by FERM BP on September 14, 1995. -Deposited internationally as 5233 under the Budapest Treaty.
- a humanized anti-HM1.24 antibody was obtained by the following method.
- Total RNA was prepared from the hybridoma HM1.24 prepared in Reference Example 1 by a conventional method. From this, cDNA encoding the mouse antibody V region was synthesized and amplified by the polymerase chain reaction (PCR) method and the 5'-RACE method. A DNA fragment containing the gene encoding the mouse V region was obtained, and each of these DNA fragments was ligated to a plasmid pUC-type cloning vector, and introduced into E. coli competent cells to obtain an E. coli transformant.
- the above plasmid was obtained from this transformant, the nucleotide sequence of the cDNA coding region in the plasmid was determined by a conventional method, and the phase of each V region was further determined. The complementarity determining region (CDR) was determined.
- cDNAs encoding the V regions of the mouse anti-HM1.24 antibody L and H chains, respectively, were inserted into the HEF vector.
- the V region CDR of the mouse anti-HM1.24 antibody was transplanted into the human antibody by CDR transplantation.
- the L chain of the human antibody RE1 was used as the L chain of the human antibody
- the FR1-3 of the human antibody HG3 was used as the H chain of the human antibody for the frame region (FR) 1-3.
- FR4 of human antibody JH6 was used.
- the amino acids of FRs in the V region of the H chain were replaced so that the CDR-grafted antibody formed an appropriate antigen-binding site.
- each of the genes was separately introduced into a HEF vector, and the humanized anti-HM1.24 antibody was humanized.
- a vector for expressing the L chain or H chain of the HM1.24 antibody was prepared.
- a cell line producing a humanized anti-HM1.24 antibody was established.
- the antigen binding activity and the binding inhibitory activity of the humanized anti-HM1.24 antibody obtained by culturing this cell line on the human amniotic membrane-derived cell line WISH were examined by Cell ELISA.
- the humanized anti-HM1.24 antibody has the same antigen-binding activity as the chimeric antibody, and the binding inhibitory activity using the biotinylated mouse anti-HM1.24 antibody is also significant. It had the same activity as the antibody or mouse antibody.
- Escherichia coli having a plasmid containing DNA encoding the L chain V region and H chain V region of the chimeric anti-HM1.24 antibody was Escherichia coli DH5a (pUC19-l.24L-g / c) and Escherichia coli, respectively.
- i cia col i DH5a (pUC19-1.24Hg a1) was submitted to the Institute of Biotechnology, Industrial Science and Technology Institute (1-3 1-3 Higashi, Tsukuba City, Ibaraki Prefecture) on August 29, 1996. , Each They were deposited internationally under the Budapest Treaty as FERM BP-5646 and FERM BP-5644, respectively.
- a plasmid containing DNA encoding the L chain V region a version (SEQ ID NO: 17) and the H chain V region r version (SEQ ID NO: 18) of the humanized anti-HM1.24 antibody The Escherichia coli having a mid was Escherichia co 1 i DH5a (pUC19-RVLa-AH-gk) and Escher i chia col i DH5a (pUC19-RVHr-AH-g a1), respectively.
- Escherichia coli having a plasmid containing DNA encoding the H chain V region s version of the humanized anti-HM1.24 antibody (SEQ ID NO: 19) is also cherichis coHDH5 (pUC19-RVHs- AHM-g a1) was reported to the Institute of Biotechnology and Industrial Technology, Institute of Industrial Science and Technology (1-3 1-3 Tsukuba-Higashi, Ibaraki Pref.) On FERM BP on September 29, 1997. -6127, deposited internationally under the Budapest Treaty.
- the human myeloma cell lines RPMI 8226 and U266 were cultured in RPMI164 medium (GIBC0-BRL) supplemented with 10% fetal calf serum (FBS).
- the myeloma cell line KP MM 2 Japanese Unexamined Patent Application Publication No. 7-236365 was cultured in RPMI164 medium supplemented with 20% fetal bovine serum.
- RNA was isolated by Chioshia phosphate Guanin / cesium chloride method than, Fast Track mRNA Isolation MRNA was purified using Kit (Invitrogen). After synthesizing cDNA from 10 g of mRNA using Not I / oligo-dT, 8 (Time Saver cDNA Synthesis Kit; Pharmacia Biotech), EcoRI adapter was ligated. The cDNA of 0.7 kbp or more was fractionated using 1.0% low melting point agarose gel (Sigma), digested with Not I, and expressed with pCOSl expression vector or AExCel1 vector (Pharmacia). Biotech) at the EcoRI / Not I site, and the library (library 1A) used for direct expression cloning (screening by panning) and the library (immunoscreening library) (library B) were used, respectively. It was constructed.
- the pC0S1 expression vector was prepared by deleting the EcoR-Notl-BamHI Adapter from HEF-PMhyl (see W092-19759) by deleting the genes contained by Ec0RI and SmaI digestion. (Takara Shuzo).
- the cells are washed with a phosphate buffer (PBS), and PBS containing 5 mM EDTA is added to wash the cells, and the cells are washed with PBS supplemented with 5% FBS and 0.02% NaN3.
- cell suspension 2 x 1 0 6 cellsZml was adjusted.
- cells were plated with anti-HM1.24 antibody coated pan. 2 hours Kiyoshi ⁇ on ning plates (described below), the plates 5% FBS, was gently washed 3 times with 0. 0 2% N a N 3 3 ml containing the PBS. After washing, the cells bound on the plate were positively added using a Hirt solution (Hitt J., Mol. Biol. 26: 365-369, 1983) (0.6% SDS, 10 mM EDTA). Mid DNA was recovered. The recovered plasmid DNA was amplified in E. coli and used for the next panning.
- PBS phosphate buffer
- PBS containing 5 mM EDTA is added to
- the Panning plate was prepared as follows. Add 3 ml of the anti-HM1.24 antibody solution (10/8111151011 ⁇ Tris-HCH9.5) to a 60 mm dish (Fa1con) and let it warm for 2 hours at room temperature. After washing with 0.15 M Na C 1 three times, add 3 ml of 5% FBS, 1 mM EDTA, 0.02% Na N 3 in PBS and add 2 ml at room temperature. Blocking was performed for a period of time. After removing the blocking solution, the panning plate was stored at 120 ° C until use.
- Immunoscreening Library B was subjected to immunoscreening using an anti-HM1.24 antibody. That, 1. 5 X 1 0 5 independent click low off Ajiraibura Lee containing down was layered together on agar with E. coli NM 5 2 2 (Pharmacia Biotech) , and 3.5 hour incubation at 4 2 ° C . After the cultivation, a nitrocellulose filter (Schleicher & Schueil) pretreated with 1 OmM IPTG was overlaid on the plate, and further cultured at 37 ° C for 3 hours.
- a nitrocellulose filter Scholaser & Schueil
- F i ter was washed with 0.05% (v / v) Tween—20 added TBS (20 mM Tris—HCl, pH 7.4, 150 mM NaCI), TBS with 1% (w / v) BSA was added, and the mixture was incubated at room temperature for 1 hour to perform blocking.
- an anti-HM1.24 antibody solution (10 g / ml blocking buffer), incubate at room temperature for 1 hour, wash, wash and dilute 5,000-fold diluted alkaline phosphatase.
- Peptide-conjugated anti-mouse Ig antiserum (picoBlue Immunoscreening kit; Stratagene) was calorie-incubated and incubated at room temperature for 1 hour. Spots that reacted with the antibody were 0.3 mg / ml nitrotrasodium, 0.1 mg / ml 5 — bromo 4 — black lip 3 — color developing solution containing indole phosphate and developed by - (1 0 0 mM T ris . HC l, pH9 5, 1 0 0 mM N a C 5 mM M g C 1 2).
- Escherichia coli containing pUC19 was named Escherichia coli DH5a (pRS38-pUC19), and on October 5, 1993, the Institute of Biotechnology and Industrial Technology (Ibaraki It has been deposited internationally under the Budapest Treaty under the deposit number FE RM BP—4 4 3 4 at Tsukuba-Higashi 1-chome 1-3).
- FACS buffer PBS (-) / 2% FCS / 0. 1% N a N 3
- HM 1 2 4 antibody added pressure to, in ice
- the reaction was performed for 30 minutes.
- the cells were resuspended in a GAM-FITC solution (25 UL g / ml in FACS buffer; Beeton Dickinson), and further reacted on ice for 30 minutes.
- the cells were resuspended in 600 u1 of a FACS buffer and determined using a FACS can (Becton Dickinson).
- UPC10 was used as a negative control antibody.
- the cell lysis buffer method 50 mM sodium folate, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Ultrasonic crushing was performed in Nonidet P-40, 0.1 mg / ml phenylmethylsulfonyl fluoride, protease inhibitor Cactenyl [Boehringer Mannheim]) to obtain a solubilized fraction.
- the solubilized fraction was added to a Sepharose 4B bead to which an anti-HM1.24 antibody was conjugated.
- the precipitate was separated by SDS-PAGE (1% ge1) and transferred to a PVDF membrane.
- the PVDF membrane was reacted with an anti-HM1.24 antibody and subsequently with a POD-antiiouse IgG, and then detected using an ECL kit (Amersham).
- P3.19 encodes a protein with an estimated molecular weight of 19.8 kDa, consisting of 180 amino acids, and has two N-type sugar chain binding motifs (Fig. 14). ). Therefore, it was considered that the presence of those having different molecular weights observed by immunoprecipitation was due to differences in N-glycan modification. In fact, the immunoprecipitate was found to bind several lectins. ing.
- SEQ ID NO: 1 shows the amino acid sequence and base sequence of the extracellular domain of the soluble HM1.24 antigen protein.
- SEQ ID NO: 2 shows an amino acid sequence and a base sequence of a fusion protein comprising a leader sequence, a FLAG peptide, and a soluble HM1.24 antigen protein.
- the leader sequence from Met at position 1 to His at position 18 is a leader sequence.
- From Asp at position 20 to Lys at position 27 are FLAG peptides.
- Gly at position 28 and Thr at position 29 are linkers.
- SEQ ID NO: 3 shows an amino acid sequence and a base sequence of a fusion protein composed of an HA peptide and a soluble HM1.24 antigen protein.
- HA peptides are from Tyr in 1st place to Ala in 9th place.
- G 1 y at position 28 and Thr at position 29 are linkers.
- SEQ ID NO: 4 shows an amino acid sequence and a base sequence of a fusion protein composed of a HA peptide and a soluble HM1.24 antigen protein having a C-terminal deleted. From Tyr in 1st position to Ala in 9th position are HA peptides. Gly at position 28 and Thr at position 29 are linkers.
- SEQ ID NO: 5 shows the determined base sequence of CGM / HA and the amino acid sequence of HA peptide.
- the HA peptide is used to connect Tyr at 1st position to Ala at 9th position.
- SEQ ID NO: 6 shows the determined amino acid sequence and base sequence of CGM / HA-HM164.
- the leader sequence from Met at position 1 to Cys at position 20 is a leader sequence.
- 22 From Tyr at position 2 to Al a at position 30 are HA peptides.
- Gly in 31 position and Thr in 32 position are linkers.
- 33 From Asn at position 3 to A at position 151 is a soluble HM1.24 antigen protein with a C-terminal deletion.
- SEQ ID NO: 7 shows the nucleotide sequence of primer CMV / L.
- SEQ ID NO: 8 shows the nucleotide sequence of primer BGH-1.
- SEQ ID NO: 9 shows the nucleotide sequence of primer So1.
- SEQ ID NO: 10 shows the nucleotide sequence of primer Sot2.
- SEQ ID NO: 11 shows the nucleotide sequence of primer So3.
- SEQ ID NO: 12 shows one base sequence of a synthetic DNA pair containing a leader sequence and a FLAG peptide sequence.
- SEQ ID NOS: 13 and 12 show the other nucleotide sequence of a synthetic DNA pair containing a leader sequence and a FLAG peptide sequence.
- SEQ ID NO: 14 shows one base sequence of a synthetic DNA pair containing the HA peptide sequence.
- SEQ ID NO: 15 shows the other base sequence of the synthetic DNA pair containing the HA peptide sequence.
- SEQ ID NO: 16 shows the amino acid sequence and the nucleotide sequence of human HM1.24 antigen protein expressed on the cell membrane.
- SEQ ID NO: 17 shows an amino acid sequence and a base sequence of an L chain V region a purge ion of a humanized anti-HM1.24 antibody.
- SEQ ID NO: 18 shows an amino acid sequence and a base sequence of an H chain V region r purge ion of a humanized anti-HM1.24 antibody.
- SEQ ID NO: 19 shows an amino acid sequence and a base sequence of H chain V region s purge ion of humanized anti-HM1.24 antibody.
- the immunological assay method of the present invention it is possible to detect or measure soluble HM1.24 antigen protein or anti-HM1.24 antibody up to about 500 pg / ml.
- Highly sensitive and rapid measurement of soluble HM1.24 antigen protein or anti-HM1.24 antibody which was previously only detectable or measurable up to 10 ng / ml with Cell Elisa, and can simultaneously measure large amounts of test samples It became.
- soluble HM1.24 antigen protein and the DNA encoding the same of the present invention are useful for measuring anti-HM1.24 antibody or soluble HM1.24 antigen protein.
- Refrigerator H -:-a # ⁇ ⁇ ⁇ ⁇ ' ⁇
- Sequence type nucleic acid
- O OVO 113 OVO OVO OIO VVV OVV wo voo m OOO OVV OVO VOO IVO 010
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26403/99A AU2640399A (en) | 1998-02-25 | 1999-02-25 | Method for immunochemically assaying anti-hm1.24 antibody |
EP99906489A EP1059533A4 (en) | 1998-02-25 | 1999-02-25 | METHOD FOR THE IMMUNOLOGICAL DETECTION OF ANTI-HM1.24 ANTIBODY |
JP2000533453A JP3609026B2 (ja) | 1998-02-25 | 1999-02-25 | 抗hm1.24抗体の免疫化学的測定方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6061398 | 1998-02-25 | ||
JP10/60613 | 1998-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999043703A1 true WO1999043703A1 (fr) | 1999-09-02 |
WO1999043703A8 WO1999043703A8 (fr) | 1999-12-02 |
Family
ID=13147307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/000885 WO1999043703A1 (fr) | 1998-02-25 | 1999-02-25 | Technique de dosage immunochimique de l'anticorps anti-hm1.24 |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1059533A4 (ja) |
JP (1) | JP3609026B2 (ja) |
AT (1) | ATE462975T1 (ja) |
AU (1) | AU2640399A (ja) |
DE (1) | DE69942215D1 (ja) |
WO (1) | WO1999043703A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077362A1 (fr) * | 2000-04-06 | 2001-10-18 | Chugai Seiyaku Kabushiki Kaisha | Dosage immunologique d'anticorps anti hm1 . 24 |
WO2002057316A1 (fr) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Nouvel anticorps monoclonal |
JP2006508094A (ja) * | 2002-10-30 | 2006-03-09 | 中外製薬株式会社 | Hm1.24を応用した癌ワクチン |
US8435530B2 (en) | 2004-06-11 | 2013-05-07 | Sbi Biotech Co., Ltd. | Methods for suppressing activity of activated interferon-producing cells |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776612B2 (en) | 2001-04-13 | 2010-08-17 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying antigen expression |
US20080299128A1 (en) | 2006-06-20 | 2008-12-04 | Myung Kim | Effect of Bst2 on inflammation |
CA2620626C (en) | 2004-12-20 | 2011-06-07 | Isu Abxis Co., Ltd. | Molecules inhibiting intercellular adhesion |
US8329186B2 (en) | 2004-12-20 | 2012-12-11 | Isu Abxis Co., Ltd | Treatment of inflammation using BST2 inhibitor |
US7740856B2 (en) | 2005-12-20 | 2010-06-22 | Isu Abxis Co., Ltd. | Effect of BST2 on inflammation |
AU2007299843B2 (en) | 2006-09-18 | 2012-03-08 | Xencor, Inc | Optimized antibodies that target HM1.24 |
WO2021081880A1 (zh) * | 2019-10-31 | 2021-05-06 | 中国科学院深圳先进技术研究院 | 一种杂交瘤细胞株及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014580A1 (fr) * | 1996-10-04 | 1998-04-09 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-hm1.24 humain reconstitue |
WO1998035698A1 (fr) * | 1997-02-12 | 1998-08-20 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs lymphocitaires |
WO1998037913A1 (fr) * | 1997-02-28 | 1998-09-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs d'activation de lymphocytes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256768A (en) * | 1985-12-13 | 1993-10-26 | The Johns Hopkins University | Expression of antigenic Epstein-Barr virus polypeptides in bacteria and their use in diagnostics |
CN1277632A (zh) * | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
-
1999
- 1999-02-25 EP EP99906489A patent/EP1059533A4/en not_active Ceased
- 1999-02-25 WO PCT/JP1999/000885 patent/WO1999043703A1/ja not_active Application Discontinuation
- 1999-02-25 AU AU26403/99A patent/AU2640399A/en not_active Abandoned
- 1999-02-25 EP EP06025157A patent/EP1757941B1/en not_active Expired - Lifetime
- 1999-02-25 DE DE69942215T patent/DE69942215D1/de not_active Expired - Lifetime
- 1999-02-25 AT AT06025157T patent/ATE462975T1/de not_active IP Right Cessation
- 1999-02-25 JP JP2000533453A patent/JP3609026B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014580A1 (fr) * | 1996-10-04 | 1998-04-09 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-hm1.24 humain reconstitue |
WO1998035698A1 (fr) * | 1997-02-12 | 1998-08-20 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs lymphocitaires |
WO1998037913A1 (fr) * | 1997-02-28 | 1998-09-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs d'activation de lymphocytes |
Non-Patent Citations (1)
Title |
---|
GOTO T, ET AL.: "A NOVEL MEMBRANE ANTIGEN SELECTIVELY EXPRESSED ON TERMINALLY DIFFERENTIATED HUMAN B CELLS", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 84, no. 06, 15 September 1994 (1994-09-15), US, pages 1922 - 1930, XP002929216, ISSN: 0006-4971 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077362A1 (fr) * | 2000-04-06 | 2001-10-18 | Chugai Seiyaku Kabushiki Kaisha | Dosage immunologique d'anticorps anti hm1 . 24 |
WO2002057316A1 (fr) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Nouvel anticorps monoclonal |
US7592005B2 (en) | 2000-12-28 | 2009-09-22 | Kirin Beer Kabushiki Kaisha | Monoclonal antibody |
JP2006508094A (ja) * | 2002-10-30 | 2006-03-09 | 中外製薬株式会社 | Hm1.24を応用した癌ワクチン |
JP4716730B2 (ja) * | 2002-10-30 | 2011-07-06 | 中外製薬株式会社 | Hm1.24を応用した癌ワクチン |
US8435530B2 (en) | 2004-06-11 | 2013-05-07 | Sbi Biotech Co., Ltd. | Methods for suppressing activity of activated interferon-producing cells |
Also Published As
Publication number | Publication date |
---|---|
EP1757941B1 (en) | 2010-03-31 |
EP1757941A1 (en) | 2007-02-28 |
DE69942215D1 (de) | 2010-05-12 |
JP3609026B2 (ja) | 2005-01-12 |
ATE462975T1 (de) | 2010-04-15 |
AU2640399A (en) | 1999-09-15 |
EP1059533A1 (en) | 2000-12-13 |
WO1999043703A8 (fr) | 1999-12-02 |
EP1059533A4 (en) | 2005-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7389424B2 (ja) | 抗gpc3抗体 | |
KR101606236B1 (ko) | Ffpe 물질 내의 인테그린 복합체의 검출용 항체 | |
JP4571496B2 (ja) | MRL/lprマウスを用いた抗体の作製 | |
JP2010190572A (ja) | IL13Ra2に対する抗体およびこれを含む診断・治療薬 | |
JPWO2008072723A1 (ja) | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 | |
WO2001077362A1 (fr) | Dosage immunologique d'anticorps anti hm1 . 24 | |
JP4984160B2 (ja) | 抗体の作製方法 | |
WO1999043703A1 (fr) | Technique de dosage immunochimique de l'anticorps anti-hm1.24 | |
AU750296B2 (en) | Antibodies against SEMP1, methods for their production and uses thereof | |
KR20180014239A (ko) | HE4a의 결정을 위해 사용되는 조성물들 및 방법들 | |
WO1999006541A1 (fr) | Anticorps du recepteur des cellules pre-b non humaines | |
EP3444273A1 (en) | Antibody specifically binding to aimp2-dx2 protein | |
AU754278B2 (en) | Monoclonal antibody against human telomerase catalytic subunit | |
WO2005017155A1 (ja) | フコーストランスポーター | |
JP3480941B2 (ja) | TGF−β阻害物質のスクリーニング方法 | |
US7338797B2 (en) | Compositions for isolating a cDNA encoding a membrane-bound protein | |
CN111448214B (zh) | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用 | |
EP1939286A1 (en) | Novel peptides | |
JP4499926B2 (ja) | 腫瘍抑制遺伝子 | |
CN114437221B (zh) | 一种癌症检测抗体及其用途 | |
CN112979798B (zh) | 一种包含c反应蛋白抗原结合结构域的分离的结合蛋白 | |
JP2008099690A (ja) | 新規ヘモポエチン受容体蛋白質、nr12 | |
AU2021206586A1 (en) | Epithelial cadherin-specific antibodies | |
CN117304319A (zh) | 靶向人clec12b蛋白的纳米抗体及其应用 | |
KR100465643B1 (ko) | 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: (EXCEPT GD) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WR | Later publication of a revised version of an international search report | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999906489 Country of ref document: EP Ref document number: 09622646 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999906489 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1999906489 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999906489 Country of ref document: EP |